<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00413</drugbank-id>
  <drugbank-id>APRD00156</drugbank-id>
  <name>Pramipexole</name>
  <description>Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD).  It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) [A176867]. It was first approved by the FDA in 1997 [L5882]. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients [A176855], leading to increased difficulty in performing activities of daily living due to symptoms that progress over time [A176858]. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 [A176861].  This increase may be attributed to an aging population along with other contributing factors [A176861].&#13;
&#13;
In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873]. RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876].</description>
  <cas-number>104632-26-0</cas-number>
  <unii>83619PEU5T</unii>
  <average-mass>211.327</average-mass>
  <monoisotopic-mass>211.114318249</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A618</ref-id>
        <pubmed-id>7664822</pubmed-id>
        <citation>Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36.</citation>
      </article>
      <article>
        <ref-id>A176855</ref-id>
        <pubmed-id>22675666</pubmed-id>
        <citation>Massano J, Bhatia KP: Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med. 2012 Jun;2(6):a008870. doi: 10.1101/cshperspect.a008870.</citation>
      </article>
      <article>
        <ref-id>A176858</ref-id>
        <pubmed-id>20123553</pubmed-id>
        <citation>Poewe W, Mahlknecht P: The clinical progression of Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S28-32. doi: 10.1016/S1353-8020(09)70831-4.</citation>
      </article>
      <article>
        <ref-id>A176861</ref-id>
        <pubmed-id>30287051</pubmed-id>
        <citation>Authors unspecified: Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):939-953. doi: 10.1016/S1474-4422(18)30295-3. Epub 2018 Oct 1.</citation>
      </article>
      <article>
        <ref-id>A176864</ref-id>
        <pubmed-id>17854248</pubmed-id>
        <citation>Aiken CB: Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry. 2007 Aug;68(8):1230-6.</citation>
      </article>
      <article>
        <ref-id>A176867</ref-id>
        <pubmed-id>18728740</pubmed-id>
        <citation>Constantinescu R: Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008 Apr;4(2):337-52.</citation>
      </article>
      <article>
        <ref-id>A176870</ref-id>
        <pubmed-id>21892895</pubmed-id>
        <citation>Antonini A, Calandrella D: Pharmacokinetic evaluation of pramipexole. Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1307-14. doi: 10.1517/17425255.2011.614232. Epub 2011 Sep 6.</citation>
      </article>
      <article>
        <ref-id>A176873</ref-id>
        <pubmed-id>18248314</pubmed-id>
        <citation>Merlino G, Serafini A, Robiony F, Valente M, Gigli GL: Clinical experience with pramipexole in the treatment of restless legs syndrome. Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):225-35. doi: 10.1517/17425255.4.2.225.</citation>
      </article>
      <article>
        <ref-id>A176876</ref-id>
        <pubmed-id>28626420</pubmed-id>
        <citation>Guo S, Huang J, Jiang H, Han C, Li J, Xu X, Zhang G, Lin Z, Xiong N, Wang T: Restless Legs Syndrome: From Pathophysiology to Clinical Diagnosis and Management. Front Aging Neurosci. 2017 Jun 2;9:171. doi: 10.3389/fnagi.2017.00171. eCollection 2017.</citation>
      </article>
      <article>
        <ref-id>A176891</ref-id>
        <pubmed-id>7754303</pubmed-id>
        <citation>Rolls ET: Neurophysiology and cognitive functions of the striatum. Rev Neurol (Paris). 1994 Aug-Sep;150(8-9):648-60.</citation>
      </article>
      <article>
        <ref-id>A176894</ref-id>
        <pubmed-id>18467168</pubmed-id>
        <citation>Galvan A, Wichmann T: Pathophysiology of parkinsonism. Clin Neurophysiol. 2008 Jul;119(7):1459-74. doi: 10.1016/j.clinph.2008.03.017. Epub 2008 May 7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L5882</ref-id>
        <title>FDA Approval package, Mirapex</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020667.cfm</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F4298</ref-id>
        <title>Pramipexole hydrochloride tablets SDS</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/298/original/PRAMIPEXOLE_DIHYDROCHLORIDE_TABLETS.pdf?1554758125</url>
      </attachment>
      <attachment>
        <ref-id>F4301</ref-id>
        <title>MedSafe NZ, Ramipex tablet information sheet</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/301/original/Ramipextab.pdf?1554758918</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>This drug is indicated for the symptomatic treatment of Parkinson’s disease [FDA label].  This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) [FDA label].  </indication>
  <pharmacodynamics>**Parkinson's Disease**&#13;
&#13;
Through the stimulation of dopamine receptors, pramipexole is thought to relieve the symptoms of Parkinson's Disease [FDA label]. The motor symptoms of Parkinson's disease occur partly due to a reduction of dopamine in the substantia nigra of the brain [A176894]. Dopamine is an essential neurotransmitter that has major effects on motor movements in humans.&#13;
&#13;
**Restless Legs Syndrome**&#13;
&#13;
Pramipexole likely restores balance to the dopaminergic system, controlling the symptoms of this condition. Restless legs syndrome is thought to occur, in part, through dysfunction of the dopaminergic system, resulting in unpleasant lower extremity symptoms [A176876], [F4301]. &#13;
&#13;
**Other effects**&#13;
&#13;
In addition to the abovementioned effects, animal studies demonstrate that pramipexole blocks dopamine synthesis, release, and turnover. Additionally, this drug is neuroprotective to dopamine neuron degeneration after ischemia or methamphetamine neurotoxicity [F4301]. </pharmacodynamics>
  <mechanism-of-action>The exact mechanism of action of pramipexole as a treatment for Parkinson's disease is unknown at this time. It is thought, however, that the ability of pramipexole to cause stimulation of the dopamine receptors in the striatum of the brain, a region that receives a vast array of neurological input and is responsible for a wide variety of functions, may be involved[A176891].  Studies performed in animals show that pramipexole influences striatal neuronal transmission rates following activation of dopamine receptors  [FDA label]. &#13;
&#13;
Pramipexole is considered a non-ergot dopamine agonist that shows specificity and strong activity at the D2 subfamily of dopamine receptors in vitro, binding selectively and dopamine D2 receptors and showing a preference for the dopamine D3 receptor subtype rather than other subtypes [A176873]. The clinical significance of this binding specificity is unknown [FDA label], [A176873]. &#13;
</mechanism-of-action>
  <toxicity>**LD50**&#13;
&#13;
Rat Oral LD 50 &gt;800 mg/kg [F4298].&#13;
&#13;
**Carcinogenicity, mutagenicity, impact on fertility**&#13;
&#13;
Pramipexole was not found to be carcinogenic in 2-year studies on mice and rats at 0.3, 2.2, and 11 times the maximum recommended human dose (MRHD). No increased incidence of tumors was observed [FDA label]. No mutagenicity was detected in various assays, including the Ames test.  Finally, pramipexole given to rat models at a dose of 2.5 mg/kg/day (5 times the maximum recommended human dose), increased estrus cycles and inhibited implantation of a fertilized ovum. Decreased levels of prolactin, a hormone necessary for implantation and maintenance of early pregnancy, were measured [FDA label]. The significance of these findings in humans is unknown. &#13;
&#13;
**Pregnancy**&#13;
&#13;
This drug is considered a pregnancy category C drug, showing teratogenic effects in animals. Currently, there no studies of pramipexole in human pregnancy. Animal reproduction studies are not always predictive of human response. This drug should only be used in pregnancy if the potential benefit outweighs the possible fetal risks [FDA label]. &#13;
&#13;
**Nursing**&#13;
&#13;
Whether pramipexole is excreted in human milk is unknown.  A decision should be made regarding the administration pramipexole during nursing, or whether to discontinue it during nursing, as many drugs are excreted in human milk. The potential exists for risk to the infant if pramipexole is, in fact, excreted in the milk [FDA label].</toxicity>
  <metabolism>This drug undergoes little metabolism in humans [FDA label]. </metabolism>
  <absorption>The bioavailability of pramipexole is higher than 90%, indicating a high level of absorption [FDA label]. </absorption>
  <half-life>About 8.5-12 hours [FDA label]. </half-life>
  <protein-binding>About 15% bound to plasma proteins [FDA label].</protein-binding>
  <route-of-elimination>The main route of pramipexole elimination, with 90% of a pramipexole dose found in the urine, almost entirely as unchanged drug [FDA label].</route-of-elimination>
  <volume-of-distribution>This drug is extensively distributed in the body with a volume of distribution of approximately 500 L [FDA label]. </volume-of-distribution>
  <clearance>Renal clearance is about 400 mL/min, indicating heavy secretion by the renal tubules [FDA label]. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.</description>
    <direct-parent>Aralkylamines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic nitrogen compounds</superclass>
    <class>Organonitrogen compounds</class>
    <subclass>Amines</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Dialkylamines</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Isothioureas</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Thiazoles</alternative-parent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Isothiourea</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Secondary aliphatic amine</substituent>
    <substituent>Secondary amine</substituent>
    <substituent>Thiazole</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001198</drugbank-id>
      <name>Pramipexole dihydrochloride monohydrate</name>
      <unii>3D867NP06J</unii>
      <cas-number>191217-81-9</cas-number>
      <inchikey>APVQOOKHDZVJEX-QTPLPEIMSA-N</inchikey>
      <average-mass>302.26</average-mass>
      <monoisotopic-mass>301.0782389</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000143</drugbank-id>
      <name>Pramipexole hydrochloride</name>
      <unii>4R2HD0M28N</unii>
      <cas-number>104632-25-9</cas-number>
      <inchikey>QMNWXHSYPXQFSK-KLXURFKVSA-N</inchikey>
      <average-mass>284.249</average-mass>
      <monoisotopic-mass>283.067673727</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(-)-Pramipexole</synonym>
    <synonym language="english" coder="iupac">(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine</synonym>
    <synonym language="spanish/german" coder="inn">Pramipexol</synonym>
    <synonym language="english/french" coder="inn/ban/usan/dcf">Pramipexole</synonym>
    <synonym language="latin" coder="inn">Pramipexolum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Act Pramipexole</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02297302</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Pramipexole</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02297310</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Pramipexole</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02297337</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Pramipexole</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02297329</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-pramipexole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02292378</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-pramipexole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02292386</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-pramipexole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02292394</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-pramipexole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02292408</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-pramipexole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347342</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-pramipexole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347350</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-pramipexole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424061</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-pramipexole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424088</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-pramipexole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424096</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-pramipexole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424118</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-pramipexole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424053</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-29</started-marketing-on>
      <ended-marketing-on>2016-11-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-pramipexole</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02363305</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-19</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-pramipexole</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02363313</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-19</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-pramipexole</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02363321</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-19</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-pramipexole</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02363348</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-19</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-pramipexole</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309017</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-26</started-marketing-on>
      <ended-marketing-on>2019-05-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-pramipexole</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309025</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-pramipexole</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309033</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-pramipexole</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309041</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-867</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.500 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5412</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.500 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4912</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.250 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5746</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-0409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-01</started-marketing-on>
      <ended-marketing-on>2013-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.250 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-392</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-05</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.250 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.500 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.750 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237145</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237146</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-26</started-marketing-on>
      <ended-marketing-on>2018-06-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237147</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-26</started-marketing-on>
      <ended-marketing-on>2018-06-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02241594</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-03-17</started-marketing-on>
      <ended-marketing-on>2018-06-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mirapex</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02297256</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0286</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on>2010-11-03</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on>2010-11-03</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapex ER</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on>2010-11-03</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/001</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.088 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/002</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.088 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/003</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.18 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/004</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.18 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/005</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.7 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/006</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.7 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/009</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/010</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/011</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.35 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/012</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.35 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/013</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.26 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/014</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.26 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/015</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.26 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/016</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.52 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/017</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.52 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/018</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.52 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/019</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.05 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/020</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.05 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/021</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.05 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/022</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/023</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/024</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/025</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/026</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/027</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/028</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.57 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/029</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.57 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/030</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.57 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/031</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.62 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/032</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.62 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mirapexin</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000134</ema-product-code>
      <ema-ma-number>EU/1/97/051/033</ema-ma-number>
      <started-marketing-on>1998-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.62 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mylan-pramipexole</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02376350</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-23</started-marketing-on>
      <ended-marketing-on>2017-05-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-pramipexole</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02376369</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-23</started-marketing-on>
      <ended-marketing-on>2017-05-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-pramipexole</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02376377</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-23</started-marketing-on>
      <ended-marketing-on>2017-05-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-pramipexole</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02376385</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-23</started-marketing-on>
      <ended-marketing-on>2017-05-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-pramipexole</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02362287</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-pramipexole</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02362295</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-pramipexole</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02362309</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-pramipexole</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02362317</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-pramipexole</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02335778</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-pramipexole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02290111</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-29</started-marketing-on>
      <ended-marketing-on>2019-05-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-pramipexole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02290138</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-29</started-marketing-on>
      <ended-marketing-on>2019-05-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-pramipexole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02290146</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-29</started-marketing-on>
      <ended-marketing-on>2019-05-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-pramipexole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02290154</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-29</started-marketing-on>
      <ended-marketing-on>2019-05-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-906</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-907</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-908</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-909</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-910</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-23</started-marketing-on>
      <ended-marketing-on>2018-12-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091683</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-23</started-marketing-on>
      <ended-marketing-on>2018-12-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091683</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-23</started-marketing-on>
      <ended-marketing-on>2018-12-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091683</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-23</started-marketing-on>
      <ended-marketing-on>2018-12-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091683</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-23</started-marketing-on>
      <ended-marketing-on>2018-12-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091683</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-23</started-marketing-on>
      <ended-marketing-on>2018-12-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091683</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-534</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-536</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-537</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-538</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367602</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-21</started-marketing-on>
      <ended-marketing-on>2019-03-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367610</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-21</started-marketing-on>
      <ended-marketing-on>2019-03-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367629</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-21</started-marketing-on>
      <ended-marketing-on>2019-03-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367645</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-21</started-marketing-on>
      <ended-marketing-on>2017-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02344270</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02344289</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02344297</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02344300</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02325802</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02325810</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02325829</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02325837</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309122</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309130</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309149</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309157</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/001</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.088 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/002</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.088 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/003</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.18 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/004</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.18 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/005</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.35 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/006</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.35 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/007</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.7 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/008</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.7 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/009</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002291</ema-product-code>
      <ema-ma-number>EU/1/11/728/010</ema-ma-number>
      <started-marketing-on>2011-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7597</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Kaiser Foundations Hospitals</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0083</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5366</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-17</started-marketing-on>
      <ended-marketing-on>2018-04-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-8019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on>2014-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090241</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-576</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-20</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-577</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-19</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-578</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-19</started-marketing-on>
      <ended-marketing-on>2013-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-19</started-marketing-on>
      <ended-marketing-on>2012-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-5034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>63739-533</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-22</started-marketing-on>
      <ended-marketing-on>2014-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>63739-534</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-22</started-marketing-on>
      <ended-marketing-on>2014-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>63739-535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-22</started-marketing-on>
      <ended-marketing-on>2014-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>63739-536</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-22</started-marketing-on>
      <ended-marketing-on>2014-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Barr Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0617</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-04</started-marketing-on>
      <ended-marketing-on>2013-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Barr Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0612</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-04</started-marketing-on>
      <ended-marketing-on>2013-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Barr Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0613</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-04</started-marketing-on>
      <ended-marketing-on>2013-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-4793</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-01</started-marketing-on>
      <ended-marketing-on>2018-06-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-0329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>North Star Rx Llc</labeller>
      <ndc-id/>
      <ndc-product-code>16714-584</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-30</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>North Star Rx Llc</labeller>
      <ndc-id/>
      <ndc-product-code>16714-585</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-30</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>North Star Rx Llc</labeller>
      <ndc-id/>
      <ndc-product-code>16714-586</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-30</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>North Star Rx Llc</labeller>
      <ndc-id/>
      <ndc-product-code>16714-589</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-30</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>North Star Rx Llc</labeller>
      <ndc-id/>
      <ndc-product-code>16714-587</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-30</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>North Star Rx Llc</labeller>
      <ndc-id/>
      <ndc-product-code>16714-588</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-30</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090190</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5249</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090190</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5250</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090190</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090190</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090190</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5281</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090190</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2912</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-30</started-marketing-on>
      <ended-marketing-on>2013-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-30</started-marketing-on>
      <ended-marketing-on>2013-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2910</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-30</started-marketing-on>
      <ended-marketing-on>2013-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3260</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-30</started-marketing-on>
      <ended-marketing-on>2013-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2913</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-30</started-marketing-on>
      <ended-marketing-on>2013-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2914</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-30</started-marketing-on>
      <ended-marketing-on>2013-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090151</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-3966</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-3645</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5250</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-15</started-marketing-on>
      <ended-marketing-on>2016-01-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-15</started-marketing-on>
      <ended-marketing-on>2016-01-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-15</started-marketing-on>
      <ended-marketing-on>2016-01-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5253</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-15</started-marketing-on>
      <ended-marketing-on>2016-01-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5254</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-15</started-marketing-on>
      <ended-marketing-on>2016-01-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>60951-933</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>60951-934</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>60951-935</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>60951-936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>60951-937</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-680</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-05</started-marketing-on>
      <ended-marketing-on>2017-01-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-681</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-05</started-marketing-on>
      <ended-marketing-on>2017-01-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-682</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-05</started-marketing-on>
      <ended-marketing-on>2017-01-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-05</started-marketing-on>
      <ended-marketing-on>2017-01-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-684</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-05</started-marketing-on>
      <ended-marketing-on>2017-01-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-628</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-629</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-630</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-632</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-09</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0584</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1331</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on>2017-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-5013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7384</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3751</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on>2012-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078551</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3752</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on>2012-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078551</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3753</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on>2012-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078551</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3754</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on>2012-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078551</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3755</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on>2012-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078551</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2189</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on>2017-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2217</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1986</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on>2016-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1704</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1705</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1707</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1713</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-04</started-marketing-on>
      <ended-marketing-on>2013-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090764</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1712</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077854</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-997</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090190</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-957</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090190</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-035</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-331</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-332</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-627</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-333</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sciegen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50228-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sciegen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50228-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sciegen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50228-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sciegen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50228-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sciegen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50228-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Sciegen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50228-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3350</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Vensun Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42543-704</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Vensun Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42543-705</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Vensun Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42543-706</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Vensun Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42543-707</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Vensun Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42543-708</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Vensun Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42543-709</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Barr Laboratories Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0614</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2010-01-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Barr Laboratories Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2010-01-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077724</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-611</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-612</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-613</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-614</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-156</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-158</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2676</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2455</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on>2018-02-06</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3280</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-916</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-917</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-918</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-919</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-920</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-922</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-921</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-574</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-575</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-576</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-577</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-578</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204518</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-746</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-747</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-748</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-749</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-750</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-751</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1196</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-793</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-05</started-marketing-on>
      <ended-marketing-on>2020-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-440</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-05</started-marketing-on>
      <ended-marketing-on>2020-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-974</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-31</started-marketing-on>
      <ended-marketing-on>2020-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-982</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-31</started-marketing-on>
      <ended-marketing-on>2020-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-8105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-214</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6704</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-611</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-612</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-613</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-614</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078894</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-094</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-095</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Rising Health, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>57237-180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Rising Health, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>57237-181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Rising Health, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>57237-182</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Rising Health, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>57237-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Rising Health, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>57237-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Rising Health, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>57237-185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-5042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Unichem Pharmaceuticals (USA), Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29300-207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Unichem Pharmaceuticals (USA), Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29300-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Unichem Pharmaceuticals (USA), Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29300-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Unichem Pharmaceuticals (USA), Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29300-270</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Unichem Pharmaceuticals (USA), Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29300-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Unichem Pharmaceuticals (USA), Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29300-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-604</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-605</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-606</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-607</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-608</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-609</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202633</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65841-734</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65841-735</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65841-736</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65841-737</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65841-738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-196</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-197</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-198</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-199</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078920</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1332</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1331</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1333</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-474</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-475</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-478</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-874</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-875</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.125 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203855</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-23</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-23</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-556</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-23</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-557</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10370-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.375 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10370-252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10370-253</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10370-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10370-254</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10370-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10370-255</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202206</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sandoz Pramipexole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315262</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Pramipexole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315270</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Pramipexole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315297</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Pramipexole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315289</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/001</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.088 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/002</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.088 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/003</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.18 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/004</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.18 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/005</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.7 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/006</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.7 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/009</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/010</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/011</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.35 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/012</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.35 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/013</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.26 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/014</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.26 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/015</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.26 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/016</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.52 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/017</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.52 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/018</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>0.52 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/019</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.05 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/020</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.05 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/021</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.05 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/022</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/023</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/024</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/025</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/026</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/027</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>3.15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/028</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.57 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/029</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.57 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/030</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>1.57 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/031</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.62 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/032</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.62 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sifrol</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000133</ema-product-code>
      <ema-ma-number>EU/1/97/050/033</ema-ma-number>
      <started-marketing-on>1997-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>2.62 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Teva-pramipexole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02269309</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-07</started-marketing-on>
      <ended-marketing-on>2018-06-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-pramipexole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02269317</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-07</started-marketing-on>
      <ended-marketing-on>2018-06-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-pramipexole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02269325</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-07</started-marketing-on>
      <ended-marketing-on>2018-06-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-pramipexole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02269333</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-07</started-marketing-on>
      <ended-marketing-on>2018-06-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Glepark</name>
      <company>Glenmark</company>
    </international-brand>
    <international-brand>
      <name>Medopexol</name>
      <company>Medochemie</company>
    </international-brand>
    <international-brand>
      <name>Miramel</name>
      <company>Clonmel</company>
    </international-brand>
    <international-brand>
      <name>Miraper</name>
      <company>Specifar</company>
    </international-brand>
    <international-brand>
      <name>Pexola</name>
      <company>Boehringer Ingelheim</company>
    </international-brand>
    <international-brand>
      <name>Sifrol ER</name>
      <company>Boehringer Ingelheim</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapexin</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Accord</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sifrol</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole + Pramipexole + Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole + Pramipexole + Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex ER</name>
      <ingredients>Pramipexole + Pramipexole + Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride Extended-Release</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole Dihydrochloride</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mirapex</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Act Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Act Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Act Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Dom-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Ava-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Ava-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Ava-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Ava-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Dom-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Dom-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Dom-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Act Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
    <mixture>
      <name>Nu-pramipexole</name>
      <ingredients>Pramipexole</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Barr Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Boehringer Ingelheim Ltd.</name>
      <url>http://www.boehringer-ingelheim.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Kaiser Foundation Hospital</name>
      <url/>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>Pharmacia Inc.</name>
      <url>http://www.pharmaciaupjohn.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Stat Rx Usa</name>
      <url>http://statrxusa.exporterus.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Vangard Labs Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Zydus Pharmaceuticals</name>
      <url>http://www.zydususa.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Boehringer ingelheim</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Mirapex 0.25 mg Tablet</description>
      <cost currency="USD">1.1</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Pramipexole 1 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Pramipexole 1.5 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Pramipexole 1 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Pramipexole 1.5 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Pramipexole 1 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Pramipexole 1.5 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Pramipexole 1 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Pramipexole 1.5 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Pramipexole 1 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Pramipexole 1.5 mg Tablet</description>
      <cost currency="USD">1.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex 1 mg Tablet</description>
      <cost currency="USD">2.2</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex 1.5 mg Tablet</description>
      <cost currency="USD">2.2</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole di-hcl 0.125 mg tablet</description>
      <cost currency="USD">2.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole di-hcl 0.25 mg tablet</description>
      <cost currency="USD">2.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole di-hcl 0.5 mg tablet</description>
      <cost currency="USD">2.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole di-hcl 1 mg tablet</description>
      <cost currency="USD">2.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole di-hcl 1.5 mg tablet</description>
      <cost currency="USD">2.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole Dihydrochloride 0.125 mg tablet</description>
      <cost currency="USD">3.07</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole Dihydrochloride 0.25 mg tablet</description>
      <cost currency="USD">3.07</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole Dihydrochloride 0.5 mg tablet</description>
      <cost currency="USD">3.07</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole Dihydrochloride 1 mg tablet</description>
      <cost currency="USD">3.07</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pramipexole Dihydrochloride 1.5 mg tablet</description>
      <cost currency="USD">3.07</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex 0.75 mg tablet</description>
      <cost currency="USD">3.28</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex 0.25 mg tablet</description>
      <cost currency="USD">3.42</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex 0.5 mg tablet</description>
      <cost currency="USD">3.42</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex 1 mg tablet</description>
      <cost currency="USD">3.42</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex 1.5 mg tablet</description>
      <cost currency="USD">3.42</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex 0.125 mg tablet</description>
      <cost currency="USD">3.48</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex er 0.375 mg tablet</description>
      <cost currency="USD">9.83</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex er 0.75 mg tablet</description>
      <cost currency="USD">9.83</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex er 1.5 mg tablet</description>
      <cost currency="USD">9.83</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex er 3 mg tablet</description>
      <cost currency="USD">9.83</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mirapex er 4.5 mg tablet</description>
      <cost currency="USD">9.83</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Pramipexole 0.25 mg Tablet</description>
      <cost currency="USD">0.62</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Pramipexole 0.25 mg Tablet</description>
      <cost currency="USD">0.62</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Pramipexole 0.25 mg Tablet</description>
      <cost currency="USD">0.62</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Pramipexole 0.25 mg Tablet</description>
      <cost currency="USD">0.62</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Pramipexole 0.25 mg Tablet</description>
      <cost currency="USD">0.62</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Anti-Dyskinesia Agents</category>
      <mesh-id>D018726</mesh-id>
    </category>
    <category>
      <category>Anti-Parkinson Agents (Dopamine Agonist)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Parkinson Drugs</category>
      <mesh-id>D000978</mesh-id>
    </category>
    <category>
      <category>Antioxidants</category>
      <mesh-id>D000975</mesh-id>
    </category>
    <category>
      <category>Benzothiazoles</category>
      <mesh-id>D052160</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Dopamine Agents</category>
      <mesh-id>D015259</mesh-id>
    </category>
    <category>
      <category>Dopamine Agonists</category>
      <mesh-id>D018491</mesh-id>
    </category>
    <category>
      <category>Drugs that are Mainly Renally Excreted</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Hypotensive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Nonergot-derivative Dopamine Receptor Agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>OCT1 substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>OCT2 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>OCT2 substrates with narrow therapeutic index</category>
      <mesh-id/>
    </category>
    <category>
      <category>Restless Legs Syndrome</category>
      <mesh-id>D012148</mesh-id>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
    <category>
      <category>Thiazoles</category>
      <mesh-id>D013844</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>.250 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>.500 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>.750 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.125 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.25 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.250 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.5 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.500 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1.5 mg</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>0.375 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>0.75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>1.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>2.25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>3.75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>4.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.088 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.18 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.35 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.7 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1.1 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>0.26 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>0.52 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>1.05 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>1.57 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>2.1 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>2.62 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>3.15 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1.0 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.125 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N04BC05">
      <level code="N04BC">Dopamine agonists</level>
      <level code="N04B">DOPAMINERGIC AGENTS</level>
      <level code="N04">ANTI-PARKINSON DRUGS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>28:36.20.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00413.pdf?1554752912</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00413.pdf?1554755213</msds>
  <patents>
    <patent>
      <number>4886812</number>
      <country>United States</country>
      <approved>1989-12-12</approved>
      <expires>2010-10-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2275379</number>
      <country>Canada</country>
      <approved>2006-11-28</approved>
      <expires>2018-01-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6001861</number>
      <country>United States</country>
      <approved>1999-12-14</approved>
      <expires>2018-01-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6194445</number>
      <country>United States</country>
      <approved>2001-02-27</approved>
      <expires>2018-01-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8679533</number>
      <country>United States</country>
      <approved>2014-03-25</approved>
      <expires>2029-09-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7695734</number>
      <country>United States</country>
      <approved>2010-04-13</approved>
      <expires>2028-04-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Take without regard to meals, however if nausea is a problem, taking the product with food may reduce its incidence.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The risk or severity of orthostatic hypotension and syncope can be increased when Pramipexole is combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The risk or severity of hypotension and orthostatic hypotension can be increased when Pramipexole is combined with Levodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00042</drugbank-id>
      <name>Botulinum Toxin Type B</name>
      <description>Botulinum Toxin Type B may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum toxin type A</name>
      <description>Botulinum toxin type A may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00150</drugbank-id>
      <name>Tryptophan</name>
      <description>Tryptophan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Fluvoxamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>Baclofen may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>Lorazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00189</drugbank-id>
      <name>Ethchlorvynol</name>
      <description>Ethchlorvynol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>Tramadol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Succinylcholine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Citalopram may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>Eletriptan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>Enflurane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Pregabalin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>Temazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>Reboxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>Butabarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>Butalbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>Methysergide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>Phenytoin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>Topiramate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>Clemastine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Atomoxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>Etomidate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>Morphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>Talbutal may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Pentobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>Valproic acid may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>Zolmitriptan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>Codeine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>Tolcapone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>Hydromorphone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>Methadone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>Cetirizine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>Trimethadione may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>Clobazam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>Chlorzoxazone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>Doxylamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Mirtazapine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00371</drugbank-id>
      <name>Meprobamate</name>
      <description>Meprobamate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>Palonosetron may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>Carisoprodol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>Eszopiclone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>Alprazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>Dexbrompheniramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>Metocurine iodide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Secobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00423</drugbank-id>
      <name>Methocarbamol</name>
      <description>Methocarbamol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>Zolpidem may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>Triprolidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>Cyproheptadine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>Meperidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>Metharbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Quinine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Dronabinol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>Fluoxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>Methohexital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>Chlordiazepoxide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>Gallamine triethiodide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>Nabilone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>Entacapone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>Oxycodone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>Dextromethorphan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>Mephenytoin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00546</drugbank-id>
      <name>Adinazolam</name>
      <description>Adinazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>Lamotrigine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Hydroxyzine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>Carbamazepine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>Cisatracurium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00574</drugbank-id>
      <name>Fenfluramine</name>
      <description>Fenfluramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>Clonidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00579</drugbank-id>
      <name>Mazindol</name>
      <description>Mazindol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>Fluticasone propionate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>Ethosuximide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>Thiopental may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>Linezolid may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>Cisapride may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>Butorphanol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>Paramethadione may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>Efavirenz may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>Clorazepic acid may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>Dexmedetomidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00645</drugbank-id>
      <name>Dyclonine</name>
      <description>Dyclonine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>Dextropropoxyphene may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>Pentazocine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>Magnesium sulfate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>Trazodone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>Metaxalone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00662</drugbank-id>
      <name>Trimethobenzamide</name>
      <description>Trimethobenzamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Sumatriptan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>Moricizine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>Midazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>Flurazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>Ergotamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>Tizanidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>Sufentanil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>Paroxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>Rocuronium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>Atracurium besylate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00737</drugbank-id>
      <name>Meclizine</name>
      <description>Meclizine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>Riluzole may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>Scopolamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>Carbinoxamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>Isoflurane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>Ethotoin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>Dolasetron may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>Olopatadine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>Clidinium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>Oxcarbazepine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>Primidone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>Halazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>Alfentanil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>Fentanyl may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>Propofol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>Acetazolamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>Diazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>Phensuximide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>Brompheniramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>Progabide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>Oxazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>Donepezil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>Nalbuphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>Methylphenobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>Levorphanol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>Benzphetamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Alprenolol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>Granisetron may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>Triazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>Remifentanil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>Ondansetron may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>Tiagabine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Zonisamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>Almotriptan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Buprenorphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>Cyclobenzaprine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Maprotiline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>Diethylpropion may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>Hexafluronium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>Felbamate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>Fexofenadine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>Naratriptan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>Rizatriptan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>Hydrocodone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Pindolol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>Zaleplon may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>Desloratadine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>Alosetron may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>Ramelteon may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>Dimenhydrinate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>Gabapentin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>Frovatriptan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>Guanfacine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>Methoxyflurane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Thalidomide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>Melatonin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>Clonazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>Diphenhydramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>Vigabatrin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>Diphenoxylate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>Sertraline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>Sibutramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01106</drugbank-id>
      <name>Levocabastine</name>
      <description>Levocabastine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01107</drugbank-id>
      <name>Methyprylon</name>
      <description>Methyprylon may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>Chlorpheniramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>Phenacemide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Doxacurium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>Nefazodone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>Thiamylal may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>Halothane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Procarbazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>Orphenadrine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>Phenobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>Escitalopram may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>Cyclizine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01178</drugbank-id>
      <name>Chlormezanone</name>
      <description>Chlormezanone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>Desflurane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>Oxymorphone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>Zopiclone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Tubocurarine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>Levetiracetam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>Dezocine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>Estazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>Dantrolene may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>Ketamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>Mivacurium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>Levacetylmethadol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>Decamethonium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Alimemazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>Ergometrine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>Fosphenytoin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>St. John's Wort may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>Metocurine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>Pancuronium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>Pipecuronium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>Vecuronium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>Amobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>Aprobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>Butobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>Heptabarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>Hexobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Lithium cation may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Penbutolol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>Methadyl acetate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01437</drugbank-id>
      <name>Glutethimide</name>
      <description>Glutethimide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01440</drugbank-id>
      <name>gamma-Hydroxybutyric acid</name>
      <description>gamma-Hydroxybutyric acid may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>MMDA may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01445</drugbank-id>
      <name>Bufotenine</name>
      <description>Bufotenine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>Dihydroetorphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>Diamorphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>Midomafetamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01463</drugbank-id>
      <name>Fencamfamin</name>
      <description>Fencamfamin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>Ethylmorphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>4-Methoxyamphetamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>Barbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>4-Bromo-2,5-dimethoxyamphetamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01488</drugbank-id>
      <name>Dimethyltryptamine</name>
      <description>Dimethyltryptamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01489</drugbank-id>
      <name>Camazepam</name>
      <description>Camazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01495</drugbank-id>
      <name>Dichloralphenazone</name>
      <description>Dichloralphenazone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>Etorphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01501</drugbank-id>
      <name>Difenoxin</name>
      <description>Difenoxin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>Tenamfetamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>Delorazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>Dextromoramide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>Desomorphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01534</drugbank-id>
      <name>Chlorhexadol</name>
      <description>Chlorhexadol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>Carfentanil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>Flunitrazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>Ethyl loflazepate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01547</drugbank-id>
      <name>Drotebanol</name>
      <description>Drotebanol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>Dihydrocodeine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01553</drugbank-id>
      <name>Cloxazolam</name>
      <description>Cloxazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>Alphacetylmethadol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>Bromazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01559</drugbank-id>
      <name>Clotiazepam</name>
      <description>Clotiazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01560</drugbank-id>
      <name>Cathinone</name>
      <description>Cathinone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>Chloral hydrate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>Dihydromorphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>Fludiazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>Metamfetamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Oxprenolol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>Ketazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>Prazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>Quazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01594</drugbank-id>
      <name>Cinolazepam</name>
      <description>Cinolazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>Nitrazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01616</drugbank-id>
      <name>Alverine</name>
      <description>Alverine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01954</drugbank-id>
      <name>Rolipram</name>
      <description>Rolipram may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>7-Nitroindazole may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02234</drugbank-id>
      <name>S-Ethylisothiourea</name>
      <description>S-Ethylisothiourea may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02852</drugbank-id>
      <name>Domoic Acid</name>
      <description>Domoic Acid may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02959</drugbank-id>
      <name>Oxitriptan</name>
      <description>Oxitriptan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03575</drugbank-id>
      <name>Phencyclidine</name>
      <description>Phencyclidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Clorgiline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>Valpromide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04325</drugbank-id>
      <name>Phenethylamine</name>
      <description>Phenethylamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04599</drugbank-id>
      <name>Aniracetam</name>
      <description>Aniracetam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04819</drugbank-id>
      <name>Methapyrilene</name>
      <description>Methapyrilene may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04821</drugbank-id>
      <name>Nomifensine</name>
      <description>Nomifensine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Urethane</name>
      <description>Urethane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>Lysergic acid diethylamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>Zimelidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04833</drugbank-id>
      <name>Methaqualone</name>
      <description>Methaqualone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>Rapacuronium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Amineptine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>Flunarizine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>Lorcaserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>Osanetant may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>Dapoxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04885</drugbank-id>
      <name>Cilansetron</name>
      <description>Cilansetron may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>Bifeprunox may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Milnacipran may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04903</drugbank-id>
      <name>Pagoclone</name>
      <description>Pagoclone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>Flibanserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04917</drugbank-id>
      <name>Renzapride</name>
      <description>Renzapride may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>Lofexidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Ezogabine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05227</drugbank-id>
      <name>APD791</name>
      <description>APD791 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05232</drugbank-id>
      <name>Tetrodotoxin</name>
      <description>Tetrodotoxin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>Methsuximide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>Pimavanserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>Brivaracetam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05542</drugbank-id>
      <name>Naronapride</name>
      <description>Naronapride may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>Naluzotan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05607</drugbank-id>
      <name>PRX-08066</name>
      <description>PRX-08066 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>BL-1020 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>Gantacurium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>Cariprazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>Mianserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>Pizotifen may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>Rufinamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>Tapentadol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>Lacosamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06264</drugbank-id>
      <name>Tolperisone</name>
      <description>Tolperisone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>Levocetirizine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>Ziconotide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>Dotarizine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>Remacemide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>Clomethiazole may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>Deramciclane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>Tramiprosate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06529</drugbank-id>
      <name>Ocinaplon</name>
      <description>Ocinaplon may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>Gaboxadol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06579</drugbank-id>
      <name>Adipiplon</name>
      <description>Adipiplon may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06582</drugbank-id>
      <name>Dextofisopam</name>
      <description>Dextofisopam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>Agomelatine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06660</drugbank-id>
      <name>Saredutant</name>
      <description>Saredutant may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>Esmirtazapine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>Vilazodone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>Nitrous oxide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06691</drugbank-id>
      <name>Mepyramine</name>
      <description>Mepyramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Desvenlafaxine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06716</drugbank-id>
      <name>Fospropofol</name>
      <description>Fospropofol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>Seproxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>Ketobemidone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06753</drugbank-id>
      <name>Triclofos</name>
      <description>Triclofos may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>Benzyl alcohol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06797</drugbank-id>
      <name>Mebutamate</name>
      <description>Mebutamate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>Wortmannin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>Sulthiame may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>Cinitapride may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08811</drugbank-id>
      <name>Tofisopam</name>
      <description>Tofisopam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08839</drugbank-id>
      <name>Serotonin</name>
      <description>Serotonin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>DPDPE may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>Gabapentin enacarbil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>Perampanel may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08892</drugbank-id>
      <name>Arbaclofen Placarbil</name>
      <description>Arbaclofen Placarbil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>Pomalidomide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>Levomilnacipran may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>Amperozide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>Indalpine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>Hexamethonium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08986</drugbank-id>
      <name>Etifoxine</name>
      <description>Etifoxine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>Eperisone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Dimetacrine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Cyamemazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>Barbexaclone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>Beclamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09014</drugbank-id>
      <name>Captodiame</name>
      <description>Captodiame may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Butriptyline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>Brotizolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09021</drugbank-id>
      <name>Benzoctamine</name>
      <description>Benzoctamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>Benactyzine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>Suvorexant may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>Tedizolid phosphate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>Cannabidiol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>Vortioxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>Tasimelteon may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09072</drugbank-id>
      <name>Sodium oxybate</name>
      <description>Sodium oxybate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>Paraldehyde may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>Stiripentol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>Eslicarbazepine acetate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>Etizolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Dosulepin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>Lofentanil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09184</drugbank-id>
      <name>Edivoxetine</name>
      <description>Edivoxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>Viloxazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09186</drugbank-id>
      <name>Nisoxetine</name>
      <description>Nisoxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09187</drugbank-id>
      <name>Lortalamine</name>
      <description>Lortalamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09190</drugbank-id>
      <name>Talopram</name>
      <description>Talopram may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Etoperidone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>RP-5063 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09247</drugbank-id>
      <name>Iproclozide</name>
      <description>Iproclozide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Tianeptine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>Ramosetron may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Oxaprotiline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>Opium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>Pyrantel may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11371</drugbank-id>
      <name>Alfaxalone</name>
      <description>Alfaxalone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>Doramectin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>Medetomidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>Xylazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>Propiopromazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>Romifidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>Tiletamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11552</drugbank-id>
      <name>Tricaine</name>
      <description>Tricaine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11555</drugbank-id>
      <name>Zolazepam</name>
      <description>Zolazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>Detomidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11582</drugbank-id>
      <name>Thiocolchicoside</name>
      <description>Thiocolchicoside may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>Normethadone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11664</drugbank-id>
      <name>Psilocybin</name>
      <description>Psilocybin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11675</drugbank-id>
      <name>Mosapride</name>
      <description>Mosapride may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11686</drugbank-id>
      <name>Iferanserin</name>
      <description>Iferanserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>Tropisetron may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>Lasmiditan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>Tetrahydrocannabivarin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>Esketamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>Brexanolone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>Etiracetam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11889</drugbank-id>
      <name>Lanicemine</name>
      <description>Lanicemine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11957</drugbank-id>
      <name>Idalopirdine</name>
      <description>Idalopirdine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12071</drugbank-id>
      <name>Vabicaserin</name>
      <description>Vabicaserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12105</drugbank-id>
      <name>Imagabalin</name>
      <description>Imagabalin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12110</drugbank-id>
      <name>m-Chlorophenylpiperazine</name>
      <description>m-Chlorophenylpiperazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12111</drugbank-id>
      <name>MK-212</name>
      <description>MK-212 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>Vinpocetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>Sarpogrelate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12177</drugbank-id>
      <name>Eplivanserin</name>
      <description>Eplivanserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12184</drugbank-id>
      <name>Gepirone</name>
      <description>Gepirone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12229</drugbank-id>
      <name>Cerlapirdine</name>
      <description>Cerlapirdine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12308</drugbank-id>
      <name>Eltanolone</name>
      <description>Eltanolone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12327</drugbank-id>
      <name>Salvinorin A</name>
      <description>Salvinorin A may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>Carisbamate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>Piclozotan may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12395</drugbank-id>
      <name>Esreboxetine</name>
      <description>Esreboxetine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>Bromperidol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12427</drugbank-id>
      <name>Orvepitant</name>
      <description>Orvepitant may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>Piritramide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12537</drugbank-id>
      <name>Benzodiazepine</name>
      <description>Benzodiazepine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12576</drugbank-id>
      <name>AZD-3043</name>
      <description>AZD-3043 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12590</drugbank-id>
      <name>Indiplon</name>
      <description>Indiplon may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>Urapidil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>Ritanserin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12725</drugbank-id>
      <name>TD-8954</name>
      <description>TD-8954 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12833</drugbank-id>
      <name>Tandospirone</name>
      <description>Tandospirone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12883</drugbank-id>
      <name>Eltoprazine</name>
      <description>Eltoprazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Opipramol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12951</drugbank-id>
      <name>Pivagabine</name>
      <description>Pivagabine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>Prothipendyl may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>Neosaxitoxin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>Hypericin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13082</drugbank-id>
      <name>Nefiracetam</name>
      <description>Nefiracetam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13099</drugbank-id>
      <name>Valnoctamide</name>
      <description>Valnoctamide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Amitriptylinoxide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>Alphaprodine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13196</drugbank-id>
      <name>Valerian</name>
      <description>Valerian may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>Butaperazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13219</drugbank-id>
      <name>Medifoxamine</name>
      <description>Medifoxamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13221</drugbank-id>
      <name>Apronalide</name>
      <description>Apronalide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Dibenzepin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>Alaproclate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13234</drugbank-id>
      <name>Propanidid</name>
      <description>Propanidid may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Quinupramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13253</drugbank-id>
      <name>Proxibarbal</name>
      <description>Proxibarbal may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>Clothiapine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>Atracurium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13303</drugbank-id>
      <name>Febarbamate</name>
      <description>Febarbamate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>Trichloroethylene may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13324</drugbank-id>
      <name>Tetrazepam</name>
      <description>Tetrazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13331</drugbank-id>
      <name>Pyrithyldione</name>
      <description>Pyrithyldione may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13335</drugbank-id>
      <name>Pinazepam</name>
      <description>Pinazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13352</drugbank-id>
      <name>Deanol</name>
      <description>Deanol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13354</drugbank-id>
      <name>Phenprobamate</name>
      <description>Phenprobamate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13357</drugbank-id>
      <name>Styramate</name>
      <description>Styramate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>Pheneturide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13370</drugbank-id>
      <name>Bromisoval</name>
      <description>Bromisoval may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13377</drugbank-id>
      <name>Vinbarbital</name>
      <description>Vinbarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>Chlorproethazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Melitracen may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>Neocitrullamon may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13402</drugbank-id>
      <name>Acetylglycinamide chloral hydrate</name>
      <description>Acetylglycinamide chloral hydrate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>Oxypertine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Lofepramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13414</drugbank-id>
      <name>Fenyramidol</name>
      <description>Fenyramidol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>Thiazinam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>Medazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>Nicomorphine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>Phenibut may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13457</drugbank-id>
      <name>Oxaflozane</name>
      <description>Oxaflozane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>Meptazinol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Iprindole may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>Emepronium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13522</drugbank-id>
      <name>Mebicar</name>
      <description>Mebicar may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>Veralipride may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13534</drugbank-id>
      <name>Gedocarnil</name>
      <description>Gedocarnil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13541</drugbank-id>
      <name>Iprazochrome</name>
      <description>Iprazochrome may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13550</drugbank-id>
      <name>Bifemelane</name>
      <description>Bifemelane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>Moperone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>Thiopropazate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13572</drugbank-id>
      <name>Emylcamate</name>
      <description>Emylcamate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13577</drugbank-id>
      <name>Allobarbital</name>
      <description>Allobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Gallamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13588</drugbank-id>
      <name>Naftidrofuryl</name>
      <description>Naftidrofuryl may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Diethyl ether may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13601</drugbank-id>
      <name>Oxiracetam</name>
      <description>Oxiracetam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>Phenoperidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>Phenazocine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13623</drugbank-id>
      <name>Fabomotizole</name>
      <description>Fabomotizole may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13642</drugbank-id>
      <name>Pridinol</name>
      <description>Pridinol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13643</drugbank-id>
      <name>Loprazolam</name>
      <description>Loprazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>Alcuronium may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13662</drugbank-id>
      <name>Hexapropymate</name>
      <description>Hexapropymate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>Fluanisone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>Mosapramine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13687</drugbank-id>
      <name>Niaprazine</name>
      <description>Niaprazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13690</drugbank-id>
      <name>Vinyl ether</name>
      <description>Vinyl ether may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13733</drugbank-id>
      <name>Methylpentynol</name>
      <description>Methylpentynol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13737</drugbank-id>
      <name>Cyclobarbital</name>
      <description>Cyclobarbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13745</drugbank-id>
      <name>Fazadinium bromide</name>
      <description>Fazadinium bromide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13754</drugbank-id>
      <name>Mephenoxalone</name>
      <description>Mephenoxalone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13770</drugbank-id>
      <name>Vinylbital</name>
      <description>Vinylbital may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Imipramine oxide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>Dixyrazine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>Tilidine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>Ethadione may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13805</drugbank-id>
      <name>Reposal</name>
      <description>Reposal may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13817</drugbank-id>
      <name>Carbromal</name>
      <description>Carbromal may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13837</drugbank-id>
      <name>Doxefazepam</name>
      <description>Doxefazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13872</drugbank-id>
      <name>Lormetazepam</name>
      <description>Lormetazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Harmaline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Brofaromine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>2,5-Dimethoxy-4-ethylthioamphetamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13948</drugbank-id>
      <name>N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine</name>
      <description>N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13984</drugbank-id>
      <name>Cyclopropane</name>
      <description>Cyclopropane may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13993</drugbank-id>
      <name>MRK-409</name>
      <description>MRK-409 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>5-methoxy-N,N-dimethyltryptamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14028</drugbank-id>
      <name>Nordazepam</name>
      <description>Nordazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>Cannabidivarin may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Aripiprazole lauroxil may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>Lithium carbonate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>Eslicarbazepine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>Perphenazine enanthate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14672</drugbank-id>
      <name>Oxazepam acetate</name>
      <description>Oxazepam acetate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14715</drugbank-id>
      <name>Cinazepam</name>
      <description>Cinazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14718</drugbank-id>
      <name>Pyrazolam</name>
      <description>Pyrazolam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14719</drugbank-id>
      <name>Bentazepam</name>
      <description>Bentazepam may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>Solriamfetol may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15197</drugbank-id>
      <name>RSV-604</name>
      <description>RSV-604 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>JNJ-26489112 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>Carfentanil, C-11 may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>Dexmethylphenidate may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>Cabergoline may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>Ropinirole may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>Dihydroergotamine may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>Pramipexole may increase the sedative activities of Apomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>Pramipexole may increase the sedative activities of Ergoloid mesylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>Pramipexole may increase the sedative activities of Pergolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>Pramipexole may increase the sedative activities of Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>Pramipexole may increase the sedative activities of Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Pramipexole may increase the sedative activities of Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>Pramipexole may increase the sedative activities of Metergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The excretion of Pramipexole can be decreased when combined with Bupropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Nicorandil may increase the hypotensive activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of adverse effects can be increased when Streptokinase is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of adverse effects can be increased when Bortezomib is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Bupivacaine is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00883</drugbank-id>
      <name>Isosorbide dinitrate</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Isosorbide dinitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Levosimendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01113</drugbank-id>
      <name>Papaverine</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01143</drugbank-id>
      <name>Amifostine</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Amifostine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01282</drugbank-id>
      <name>Carbetocin</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Carbetocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01612</drugbank-id>
      <name>Amyl Nitrite</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Amyl Nitrite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04899</drugbank-id>
      <name>Nesiritide</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Nesiritide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Azilsartan medoxomil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Isoxsuprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09112</drugbank-id>
      <name>Nitrous acid</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Nitrous acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Fimasartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Pramipexole may increase the hypotensive activities of Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cyclosporine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>Icosapent may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>Cefotiam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00267</drugbank-id>
      <name>Cefmenoxime</name>
      <description>Cefmenoxime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00274</drugbank-id>
      <name>Cefmetazole</name>
      <description>Cefmetazole may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>Pamidronic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>Tenofovir disoproxil may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Indomethacin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>Cidofovir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Triamterene may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00430</drugbank-id>
      <name>Cefpiramide</name>
      <description>Cefpiramide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00438</drugbank-id>
      <name>Ceftazidime</name>
      <description>Ceftazidime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00447</drugbank-id>
      <name>Loracarbef</name>
      <description>Loracarbef may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>Framycetin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>Cefalotin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Nabumetone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Ketorolac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Tenoxicam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>Amikacin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Celecoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>Cefotaxime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Tolmetin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>Foscarnet may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>Rofecoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Piroxicam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>Methotrexate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>Cephalexin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Fenoprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00577</drugbank-id>
      <name>Valaciclovir</name>
      <description>Valaciclovir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Valdecoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Diclofenac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Sulindac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00626</drugbank-id>
      <name>Bacitracin</name>
      <description>Bacitracin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>Amphotericin B may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>Tobramycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00689</drugbank-id>
      <name>Cephaloglycin</name>
      <description>Cephaloglycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>Flurbiprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00718</drugbank-id>
      <name>Adefovir dipivoxil</name>
      <description>Adefovir dipivoxil may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Pentamidine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>Mannitol may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Etodolac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Mefenamic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>Acyclovir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>Gentamicin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Phenylbutazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Meloxicam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Cefaclor may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>Etacrynic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00923</drugbank-id>
      <name>Ceforanide</name>
      <description>Ceforanide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Meclofenamic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>Netilmicin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>Carboplatin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Oxaprozin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>Neomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Hydrochlorothiazide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ketoprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>Ibuprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01066</drugbank-id>
      <name>Cefditoren</name>
      <description>Cefditoren may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>Atazanavir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>Streptomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>Colistimethate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01112</drugbank-id>
      <name>Cefuroxime</name>
      <description>Cefuroxime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01139</drugbank-id>
      <name>Cefapirin</name>
      <description>Cefapirin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>Cefadroxil may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01150</drugbank-id>
      <name>Cefprozil</name>
      <description>Cefprozil may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>Kanamycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>Ceftriaxone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Lumiracoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>Cefamandole may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>Cefazolin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01328</drugbank-id>
      <name>Cefonicid</name>
      <description>Cefonicid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>Cefoperazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01330</drugbank-id>
      <name>Cefotetan</name>
      <description>Cefotetan may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01331</drugbank-id>
      <name>Cefoxitin</name>
      <description>Cefoxitin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>Ceftizoxime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>Cefradine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Salsalate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>Choline magnesium trisalicylate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01413</drugbank-id>
      <name>Cefepime</name>
      <description>Cefepime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>Cefacetrile may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>Ceftibuten may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01416</drugbank-id>
      <name>Cefpodoxime</name>
      <description>Cefpodoxime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>Antrafenine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>Paromomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>Aminophenazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Antipyrine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Lopinavir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Etoricoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02247</drugbank-id>
      <name>Hydrolyzed Cephalothin</name>
      <description>Hydrolyzed Cephalothin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03450</drugbank-id>
      <name>Cephalothin Group</name>
      <description>Cephalothin Group may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Oxyphenbutazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>Ribostamycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>Geneticin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>Niflumic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04570</drugbank-id>
      <name>Latamoxef</name>
      <description>Latamoxef may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>Apramycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>Gentamicin C1a may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>Neamine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Benoxaprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Metamizole may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Zomepirac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04918</drugbank-id>
      <name>Ceftobiprole</name>
      <description>Ceftobiprole may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>Cimicoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06590</drugbank-id>
      <name>Ceftaroline fosamil</name>
      <description>Ceftaroline fosamil may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>Arbekacin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Lornoxicam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Aceclofenac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Zaltoprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Azapropazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>Felbinac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>Puromycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>Parecoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Salicylamide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Kebuzone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Isoxicam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Indoprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Ibuproxam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>Floctafenine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Fenbufen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Etofenamate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Epirizole may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>Cefaloridine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09062</drugbank-id>
      <name>Cefminox</name>
      <description>Cefminox may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>Benzydamine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Loxoprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>Dexibuprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>Dexketoprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Droxicam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>Tolfenamic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>Firocoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Clonixin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>Morniflumate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Propacetamol may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>Talniflumate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>Tenofovir alafenamide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11367</drugbank-id>
      <name>Cefroxadine</name>
      <description>Cefroxadine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>Robenacoxib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Tepoxalin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>Dihydrostreptomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Flunixin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>Hygromycin B may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11935</drugbank-id>
      <name>Flomoxef</name>
      <description>Flomoxef may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12151</drugbank-id>
      <name>Brincidofovir</name>
      <description>Brincidofovir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>Sisomicin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Tinoridine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>Alclofenac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>Fentiazac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>Suxibuzone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13266</drugbank-id>
      <name>Cefatrizine</name>
      <description>Cefatrizine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>Dibekacin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>Micronomicin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>Bumadizone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>Alminoprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>Flunoxaprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>Feprazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>Difenpiramide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>Nifenazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>Lonazolac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13461</drugbank-id>
      <name>Cefcapene</name>
      <description>Cefcapene may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13470</drugbank-id>
      <name>Cefodizime</name>
      <description>Cefodizime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>Tenidap may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13499</drugbank-id>
      <name>Cefsulodin</name>
      <description>Cefsulodin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>Bendazac may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13504</drugbank-id>
      <name>Cefetamet</name>
      <description>Cefetamet may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>Pranoprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>Propyphenazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>Proglumetacin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>Guacetisal may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>Isepamicin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>Ethenzamide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>Carbaspirin calcium may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>Mofebutazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13638</drugbank-id>
      <name>Cefbuperazone</name>
      <description>Cefbuperazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>Proquazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>Benorilate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13667</drugbank-id>
      <name>Cefozopran</name>
      <description>Cefozopran may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>Bekanamycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13682</drugbank-id>
      <name>Cefpirome</name>
      <description>Cefpirome may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>Pirprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13778</drugbank-id>
      <name>Cefazedone</name>
      <description>Cefazedone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>Acemetacin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13821</drugbank-id>
      <name>Ceftezole</name>
      <description>Ceftezole may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>Imidazole salicylate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13868</drugbank-id>
      <name>Adefovir</name>
      <description>Adefovir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>SC-236 may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>NS-398 may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>Tenofovir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>Inotersen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01438</drugbank-id>
      <name>Phenazopyridine</name>
      <description>Phenazopyridine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>Givosiran may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>Leuprolide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Goserelin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>Salmon Calcitonin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>Desmopressin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>Aldesleukin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>Daptomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>Tositumomab may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>Cyanocobalamin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Folic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00165</drugbank-id>
      <name>Pyridoxine</name>
      <description>Pyridoxine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>Cevimeline may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>Carbidopa may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>Fluconazole may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00198</drugbank-id>
      <name>Oseltamivir</name>
      <description>Oseltamivir may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00200</drugbank-id>
      <name>Hydroxocobalamin</name>
      <description>Hydroxocobalamin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>Pantoprazole may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00225</drugbank-id>
      <name>Gadodiamide</name>
      <description>Gadodiamide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>Benzatropine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>Doxycycline may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>Carmustine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Isradipine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00271</drugbank-id>
      <name>Diatrizoate</name>
      <description>Diatrizoate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>Liothyronine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Acarbose may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>Bleomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Etonogestrel may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Ropivacaine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00303</drugbank-id>
      <name>Ertapenem</name>
      <description>Ertapenem may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Ibutilide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Acetaminophen may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>Piperacillin may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>Floxuridine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Nitroprusside may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00330</drugbank-id>
      <name>Ethambutol</name>
      <description>Ethambutol may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00339</drugbank-id>
      <name>Pyrazinamide</name>
      <description>Pyrazinamide may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Megestrol acetate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00355</drugbank-id>
      <name>Aztreonam</name>
      <description>Aztreonam may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Sulfadiazine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>Sucralfate may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Timolol may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>Dexrazoxane may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>Sorafenib may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>Nisoldipine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00415</drugbank-id>
      <name>Ampicillin</name>
      <description>Pramipexole may decrease the excretion rate of Ampicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>Pramipexole may decrease the excretion rate of Trifluridine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>Pramipexole may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Pramipexole may decrease the excretion rate of Allopurinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>Pramipexole may decrease the excretion rate of Gemcitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>Pramipexole may decrease the excretion rate of Lenalidomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Pramipexole may decrease the excretion rate of Fosinopril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>Pramipexole may decrease the excretion rate of Flutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Pramipexole may decrease the excretion rate of Metolazone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>Pramipexole may decrease the excretion rate of Cefdinir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Pramipexole may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00548</drugbank-id>
      <name>Azelaic acid</name>
      <description>Pramipexole may decrease the excretion rate of Azelaic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>Pramipexole may decrease the excretion rate of Pentostatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>Pramipexole may decrease the excretion rate of Methoxsalen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00558</drugbank-id>
      <name>Zanamivir</name>
      <description>Pramipexole may decrease the excretion rate of Zanamivir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>Pramipexole may decrease the excretion rate of Fondaparinux which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>Pramipexole may decrease the excretion rate of Levocarnitine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>Pramipexole may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00597</drugbank-id>
      <name>Gadoteridol</name>
      <description>Pramipexole may decrease the excretion rate of Gadoteridol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Pramipexole may decrease the excretion rate of Labetalol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>Pramipexole may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Pramipexole may decrease the excretion rate of Chloroquine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Pramipexole may decrease the excretion rate of Bisoprolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Pramipexole may decrease the excretion rate of Testosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Pramipexole may decrease the excretion rate of Clofarabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>Pramipexole may decrease the excretion rate of Prednisone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>Pramipexole may decrease the excretion rate of Dyphylline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Pramipexole may decrease the excretion rate of Mecamylamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>Pramipexole may decrease the excretion rate of Nilutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Pramipexole may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Pramipexole may decrease the excretion rate of Galantamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Pramipexole may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>Pramipexole may decrease the excretion rate of Phentolamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Pramipexole may decrease the excretion rate of Furosemide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Pramipexole may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Pramipexole may decrease the excretion rate of Tamsulosin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>Pramipexole may decrease the excretion rate of Lamivudine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00713</drugbank-id>
      <name>Oxacillin</name>
      <description>Pramipexole may decrease the excretion rate of Oxacillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00716</drugbank-id>
      <name>Nedocromil</name>
      <description>Pramipexole may decrease the excretion rate of Nedocromil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Pramipexole may decrease the excretion rate of Lisinopril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>Pramipexole may decrease the excretion rate of Thiabendazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>Pramipexole may decrease the excretion rate of Nateglinide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00733</drugbank-id>
      <name>Pralidoxime</name>
      <description>Pramipexole may decrease the excretion rate of Pralidoxime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Pramipexole may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>Pramipexole may decrease the excretion rate of Tetracycline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00760</drugbank-id>
      <name>Meropenem</name>
      <description>Pramipexole may decrease the excretion rate of Meropenem which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00761</drugbank-id>
      <name>Potassium chloride</name>
      <description>Pramipexole may decrease the excretion rate of Potassium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>Pramipexole may decrease the excretion rate of Methimazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Pramipexole may decrease the excretion rate of Tirofiban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Pramipexole may decrease the excretion rate of Propantheline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00789</drugbank-id>
      <name>Gadopentetic acid</name>
      <description>Pramipexole may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Pramipexole may decrease the excretion rate of Perindopril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Pramipexole may decrease the excretion rate of Dicyclomine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pramipexole may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Pramipexole may decrease the excretion rate of Indapamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>Pramipexole may decrease the excretion rate of Ribavirin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>Pramipexole may decrease the excretion rate of Tadalafil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00828</drugbank-id>
      <name>Fosfomycin</name>
      <description>Pramipexole may decrease the excretion rate of Fosfomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>Pramipexole may decrease the excretion rate of Tolazamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>Pramipexole may decrease the excretion rate of Dobutamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>Pramipexole may decrease the excretion rate of Dacarbazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>Pramipexole may decrease the excretion rate of Temozolomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>Pramipexole may decrease the excretion rate of Terbutaline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Pramipexole may decrease the excretion rate of Bumetanide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00894</drugbank-id>
      <name>Testolactone</name>
      <description>Pramipexole may decrease the excretion rate of Testolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Pramipexole may decrease the excretion rate of Didanosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Pramipexole may decrease the excretion rate of Tinidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>Pramipexole may decrease the excretion rate of Azacitidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>Pramipexole may decrease the excretion rate of Isoniazid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>Pramipexole may decrease the excretion rate of Mepivacaine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Pramipexole may decrease the excretion rate of Methyldopa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>Pramipexole may decrease the excretion rate of Azathioprine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00995</drugbank-id>
      <name>Auranofin</name>
      <description>Pramipexole may decrease the excretion rate of Auranofin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>Pramipexole may decrease the excretion rate of Salbutamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Pramipexole may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>Pramipexole may decrease the excretion rate of Edrophonium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>Pramipexole may decrease the excretion rate of Metyrapone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Pramipexole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>Pramipexole may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01022</drugbank-id>
      <name>Phylloquinone</name>
      <description>Pramipexole may decrease the excretion rate of Phylloquinone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Pramipexole may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>Pramipexole may decrease the excretion rate of Topotecan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Pramipexole may decrease the excretion rate of Tolterodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>Pramipexole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>Pramipexole may decrease the excretion rate of Memantine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>Pramipexole may decrease the excretion rate of Lubiprostone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>Pramipexole may decrease the excretion rate of Abacavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>Pramipexole may decrease the excretion rate of Amoxicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Pramipexole may decrease the excretion rate of Glipizide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>Pramipexole may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>Pramipexole may decrease the excretion rate of Flucytosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>Pramipexole may decrease the excretion rate of Capecitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>Pramipexole may decrease the excretion rate of Nifedipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>Pramipexole may decrease the excretion rate of Tolbutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Pramipexole may decrease the excretion rate of Rabeprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>Pramipexole may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Pramipexole may decrease the excretion rate of Flavoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>Pramipexole may decrease the excretion rate of Trimetrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Pramipexole may decrease the excretion rate of Cilostazol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>Pramipexole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>Pramipexole may decrease the excretion rate of Guanethidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>Pramipexole may decrease the excretion rate of Ifosfamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>Pramipexole may decrease the excretion rate of Naloxone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Pramipexole may decrease the excretion rate of Nadolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01205</drugbank-id>
      <name>Flumazenil</name>
      <description>Pramipexole may decrease the excretion rate of Flumazenil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01213</drugbank-id>
      <name>Fomepizole</name>
      <description>Pramipexole may decrease the excretion rate of Fomepizole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>Pramipexole may decrease the excretion rate of Budesonide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Pramipexole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>Pramipexole may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01249</drugbank-id>
      <name>Iodixanol</name>
      <description>Pramipexole may decrease the excretion rate of Iodixanol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>Pramipexole may decrease the excretion rate of Sitagliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>Pramipexole may decrease the excretion rate of Arformoterol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Pramipexole may decrease the excretion rate of Hydralazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>Pramipexole may decrease the excretion rate of Colchicine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Pramipexole may decrease the excretion rate of Tiotropium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>Pramipexole may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01427</drugbank-id>
      <name>Amrinone</name>
      <description>Pramipexole may decrease the excretion rate of Amrinone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01428</drugbank-id>
      <name>Oxybenzone</name>
      <description>Pramipexole may decrease the excretion rate of Oxybenzone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>Pramipexole may decrease the excretion rate of Allylestrenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01550</drugbank-id>
      <name>Fenproporex</name>
      <description>Pramipexole may decrease the excretion rate of Fenproporex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01610</drugbank-id>
      <name>Valganciclovir</name>
      <description>Pramipexole may decrease the excretion rate of Valganciclovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>Pramipexole may decrease the excretion rate of Sorbitol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Pramipexole may decrease the excretion rate of Roflumilast which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Pramipexole may decrease the excretion rate of Topiroxostat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Pramipexole may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>Pramipexole may decrease the excretion rate of Pegaptanib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Pramipexole may decrease the excretion rate of Clevidipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05018</drugbank-id>
      <name>Migalastat</name>
      <description>Pramipexole may decrease the excretion rate of Migalastat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Pramipexole may decrease the excretion rate of Apremilast which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06154</drugbank-id>
      <name>Pentaerythritol tetranitrate</name>
      <description>Pramipexole may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>Pramipexole may decrease the excretion rate of Ipilimumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Pramipexole may decrease the excretion rate of Icatibant which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Pramipexole may decrease the excretion rate of Alogliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Pramipexole may decrease the excretion rate of Prasugrel which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06211</drugbank-id>
      <name>Doripenem</name>
      <description>Pramipexole may decrease the excretion rate of Doripenem which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Pramipexole may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06230</drugbank-id>
      <name>Nalmefene</name>
      <description>Pramipexole may decrease the excretion rate of Nalmefene which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>Pramipexole may decrease the excretion rate of Droxidopa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Pramipexole may decrease the excretion rate of Saxagliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Pramipexole may decrease the excretion rate of Telavancin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06623</drugbank-id>
      <name>Flupirtine</name>
      <description>Pramipexole may decrease the excretion rate of Flupirtine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>Pramipexole may decrease the excretion rate of Dalfampridine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Pramipexole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>Pramipexole may decrease the excretion rate of Fesoterodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06705</drugbank-id>
      <name>Gadofosveset trisodium</name>
      <description>Pramipexole may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Pramipexole may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>Pramipexole may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06782</drugbank-id>
      <name>Dimercaprol</name>
      <description>Pramipexole may decrease the excretion rate of Dimercaprol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06796</drugbank-id>
      <name>Mangafodipir</name>
      <description>Pramipexole may decrease the excretion rate of Mangafodipir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06800</drugbank-id>
      <name>Methylnaltrexone</name>
      <description>Pramipexole may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06809</drugbank-id>
      <name>Plerixafor</name>
      <description>Pramipexole may decrease the excretion rate of Plerixafor which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>Pramipexole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06823</drugbank-id>
      <name>Tiopronin</name>
      <description>Pramipexole may decrease the excretion rate of Tiopronin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06824</drugbank-id>
      <name>Triethylenetetramine</name>
      <description>Pramipexole may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08824</drugbank-id>
      <name>Ioflupane I-123</name>
      <description>Pramipexole may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08826</drugbank-id>
      <name>Deferiprone</name>
      <description>Pramipexole may decrease the excretion rate of Deferiprone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08840</drugbank-id>
      <name>N-methylnicotinamide</name>
      <description>Pramipexole may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>Pramipexole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>Pramipexole may decrease the excretion rate of Mirabegron which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>Pramipexole may decrease the excretion rate of Peginesatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Pramipexole may decrease the excretion rate of Aclidinium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>Pramipexole may decrease the excretion rate of Enzalutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08900</drugbank-id>
      <name>Teduglutide</name>
      <description>Pramipexole may decrease the excretion rate of Teduglutide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>Pramipexole may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>Pramipexole may decrease the excretion rate of Formestane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Pramipexole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>Pramipexole may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>Pramipexole may decrease the excretion rate of Trametinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>Pramipexole may decrease the excretion rate of Macitentan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>Pramipexole may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08964</drugbank-id>
      <name>Gemeprost</name>
      <description>Pramipexole may decrease the excretion rate of Gemeprost which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>Pramipexole may decrease the excretion rate of Ledipasvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Pramipexole may decrease the excretion rate of Empagliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09050</drugbank-id>
      <name>Ceftolozane</name>
      <description>Pramipexole may decrease the excretion rate of Ceftolozane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin alfa</name>
      <description>Pramipexole may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Pramipexole may decrease the excretion rate of Edoxaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09081</drugbank-id>
      <name>Idebenone</name>
      <description>Pramipexole may decrease the excretion rate of Idebenone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>Pramipexole may decrease the excretion rate of Vilanterol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>Pramipexole may decrease the excretion rate of Trimebutine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>Pramipexole may decrease the excretion rate of Tixocortol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>Pramipexole may decrease the excretion rate of Ancestim which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Pramipexole may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09106</drugbank-id>
      <name>Hydroxyethyl Starch</name>
      <description>Pramipexole may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09111</drugbank-id>
      <name>Pentastarch</name>
      <description>Pramipexole may decrease the excretion rate of Pentastarch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09121</drugbank-id>
      <name>Aurothioglucose</name>
      <description>Pramipexole may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Pramipexole may decrease the excretion rate of Dienogest which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09129</drugbank-id>
      <name>Chromic chloride</name>
      <description>Pramipexole may decrease the excretion rate of Chromic chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09132</drugbank-id>
      <name>Gadoteric acid</name>
      <description>Pramipexole may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09133</drugbank-id>
      <name>Iothalamic acid</name>
      <description>Pramipexole may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09134</drugbank-id>
      <name>Ioversol</name>
      <description>Pramipexole may decrease the excretion rate of Ioversol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09135</drugbank-id>
      <name>Ioxilan</name>
      <description>Pramipexole may decrease the excretion rate of Ioxilan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09136</drugbank-id>
      <name>Isosulfan blue</name>
      <description>Pramipexole may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09137</drugbank-id>
      <name>Technetium Tc-99m mebrofenin</name>
      <description>Pramipexole may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Pramipexole may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09148</drugbank-id>
      <name>Florbetaben (18F)</name>
      <description>Pramipexole may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09149</drugbank-id>
      <name>Florbetapir (18F)</name>
      <description>Pramipexole may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09156</drugbank-id>
      <name>Iopromide</name>
      <description>Pramipexole may decrease the excretion rate of Iopromide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09163</drugbank-id>
      <name>Technetium Tc-99m exametazime</name>
      <description>Pramipexole may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09164</drugbank-id>
      <name>Technetium Tc-99m disofenin</name>
      <description>Pramipexole may decrease the excretion rate of Technetium Tc-99m disofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09165</drugbank-id>
      <name>Technetium Tc-99m pyrophosphate</name>
      <description>Pramipexole may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>Pramipexole may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Pramipexole may decrease the excretion rate of Arotinolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Pramipexole may decrease the excretion rate of Moxisylyte which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09209</drugbank-id>
      <name>Pholcodine</name>
      <description>Pramipexole may decrease the excretion rate of Pholcodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09210</drugbank-id>
      <name>Piracetam</name>
      <description>Pramipexole may decrease the excretion rate of Piracetam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>Pramipexole may decrease the excretion rate of Bisoxatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Pramipexole may decrease the excretion rate of Dextran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>Pramipexole may decrease the excretion rate of Tegafur which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09257</drugbank-id>
      <name>Gimeracil</name>
      <description>Pramipexole may decrease the excretion rate of Gimeracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Pramipexole may decrease the excretion rate of Imidafenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>Pramipexole may decrease the excretion rate of Idarucizumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Pramipexole may decrease the excretion rate of Lixisenatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>Pramipexole may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09276</drugbank-id>
      <name>Sodium aurothiomalate</name>
      <description>Pramipexole may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>Pramipexole may decrease the excretion rate of Choline C 11 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Pramipexole may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>Pramipexole may decrease the excretion rate of Sacubitril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09301</drugbank-id>
      <name>Chondroitin sulfate</name>
      <description>Pramipexole may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Pramipexole may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Pramipexole may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09320</drugbank-id>
      <name>Procaine benzylpenicillin</name>
      <description>Pramipexole may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09324</drugbank-id>
      <name>Sulbactam</name>
      <description>Pramipexole may decrease the excretion rate of Sulbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09325</drugbank-id>
      <name>Sodium fluoride</name>
      <description>Pramipexole may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>Pramipexole may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>Pramipexole may decrease the excretion rate of Mersalyl which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09344</drugbank-id>
      <name>Invert sugar</name>
      <description>Pramipexole may decrease the excretion rate of Invert sugar which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09357</drugbank-id>
      <name>Dexpanthenol</name>
      <description>Pramipexole may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09394</drugbank-id>
      <name>Phosphoric acid</name>
      <description>Pramipexole may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09395</drugbank-id>
      <name>Sodium acetate</name>
      <description>Pramipexole may decrease the excretion rate of Sodium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>Pramipexole may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>Pramipexole may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>Pramipexole may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Pramipexole may decrease the excretion rate of Enalaprilat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Pramipexole may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>Pramipexole may decrease the excretion rate of Acrivastine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09496</drugbank-id>
      <name>Octinoxate</name>
      <description>Pramipexole may decrease the excretion rate of Octinoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09502</drugbank-id>
      <name>Fludeoxyglucose (18F)</name>
      <description>Pramipexole may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09546</drugbank-id>
      <name>Iobenguane sulfate I-123</name>
      <description>Pramipexole may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>Pramipexole may decrease the excretion rate of Ixazomib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>Pramipexole may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11090</drugbank-id>
      <name>Potassium nitrate</name>
      <description>Pramipexole may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11098</drugbank-id>
      <name>Potassium bicarbonate</name>
      <description>Pramipexole may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11102</drugbank-id>
      <name>N-acetyltyrosine</name>
      <description>Pramipexole may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11114</drugbank-id>
      <name>Eucalyptus oil</name>
      <description>Pramipexole may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11127</drugbank-id>
      <name>Selenious acid</name>
      <description>Pramipexole may decrease the excretion rate of Selenious acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11135</drugbank-id>
      <name>Selenium</name>
      <description>Pramipexole may decrease the excretion rate of Selenium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11136</drugbank-id>
      <name>Chromium</name>
      <description>Pramipexole may decrease the excretion rate of Chromium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11145</drugbank-id>
      <name>Oxyquinoline</name>
      <description>Pramipexole may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11164</drugbank-id>
      <name>Bicisate</name>
      <description>Pramipexole may decrease the excretion rate of Bicisate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11251</drugbank-id>
      <name>Tocopherol</name>
      <description>Pramipexole may decrease the excretion rate of Tocopherol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>Pramipexole may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11328</drugbank-id>
      <name>Tetradecyl hydrogen sulfate (ester)</name>
      <description>Pramipexole may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11338</drugbank-id>
      <name>Clove oil</name>
      <description>Pramipexole may decrease the excretion rate of Clove oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Pramipexole may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11364</drugbank-id>
      <name>Pidotimod</name>
      <description>Pramipexole may decrease the excretion rate of Pidotimod which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>Pramipexole may decrease the excretion rate of Lesinurad which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11577</drugbank-id>
      <name>Indigotindisulfonic acid</name>
      <description>Pramipexole may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>Pramipexole may decrease the excretion rate of Etafedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Pramipexole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11691</drugbank-id>
      <name>Naldemedine</name>
      <description>Pramipexole may decrease the excretion rate of Naldemedine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>Pramipexole may decrease the excretion rate of Valbenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Pramipexole may decrease the excretion rate of Delafloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11989</drugbank-id>
      <name>Benznidazole</name>
      <description>Pramipexole may decrease the excretion rate of Benznidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12007</drugbank-id>
      <name>Isoflavone</name>
      <description>Pramipexole may decrease the excretion rate of Isoflavone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12107</drugbank-id>
      <name>Vaborbactam</name>
      <description>Pramipexole may decrease the excretion rate of Vaborbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>Pramipexole may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Pramipexole may decrease the excretion rate of Propiverine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12783</drugbank-id>
      <name>Benserazide</name>
      <description>Pramipexole may decrease the excretion rate of Benserazide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>Pramipexole may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13145</drugbank-id>
      <name>Nedaplatin</name>
      <description>Pramipexole may decrease the excretion rate of Nedaplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13156</drugbank-id>
      <name>Inosine pranobex</name>
      <description>Pramipexole may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13178</drugbank-id>
      <name>Inositol</name>
      <description>Pramipexole may decrease the excretion rate of Inositol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13185</drugbank-id>
      <name>Oxabolone cipionate</name>
      <description>Pramipexole may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13191</drugbank-id>
      <name>Phosphocreatine</name>
      <description>Pramipexole may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13269</drugbank-id>
      <name>Dichlorobenzyl alcohol</name>
      <description>Pramipexole may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>Pramipexole may decrease the excretion rate of Ipecac which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>Pramipexole may decrease the excretion rate of Almasilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>Pramipexole may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>Pramipexole may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Pramipexole may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Pramipexole may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Pramipexole may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Pramipexole may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>Pramipexole may decrease the excretion rate of Patent Blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14007</drugbank-id>
      <name>Pentetic acid</name>
      <description>Pramipexole may decrease the excretion rate of Pentetic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14184</drugbank-id>
      <name>Cinnamaldehyde</name>
      <description>Pramipexole may decrease the excretion rate of Cinnamaldehyde which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14186</drugbank-id>
      <name>Cinnamyl alcohol</name>
      <description>Pramipexole may decrease the excretion rate of Cinnamyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14498</drugbank-id>
      <name>Potassium acetate</name>
      <description>Pramipexole may decrease the excretion rate of Potassium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>Pramipexole may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14526</drugbank-id>
      <name>Chromic citrate</name>
      <description>Pramipexole may decrease the excretion rate of Chromic citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14527</drugbank-id>
      <name>Chromic nitrate</name>
      <description>Pramipexole may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14528</drugbank-id>
      <name>Chromium gluconate</name>
      <description>Pramipexole may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14529</drugbank-id>
      <name>Chromium nicotinate</name>
      <description>Pramipexole may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14530</drugbank-id>
      <name>Chromous sulfate</name>
      <description>Pramipexole may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06815</drugbank-id>
      <name>Pyrithione</name>
      <description>Pramipexole may decrease the excretion rate of Pyrithione which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11121</drugbank-id>
      <name>Chloroxylenol</name>
      <description>Pramipexole may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>Pramipexole may decrease the excretion rate of Prucalopride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>Pramipexole may decrease the excretion rate of Resorcinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15593</drugbank-id>
      <name>Golodirsen</name>
      <description>Pramipexole may decrease the excretion rate of Golodirsen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>Pramipexole may decrease the excretion rate of Capreomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Pramipexole may decrease the excretion rate of Digoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>Pramipexole may decrease the excretion rate of Vancomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>Pramipexole may decrease the excretion rate of Pemetrexed which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Pramipexole may decrease the excretion rate of Warfarin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00879</drugbank-id>
      <name>Emtricitabine</name>
      <description>Pramipexole may decrease the excretion rate of Emtricitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>Pramipexole may decrease the excretion rate of Isotretinoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>Pramipexole may decrease the excretion rate of Plazomicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>Pramipexole may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>Pramipexole may decrease the excretion rate of Lithium citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14508</drugbank-id>
      <name>Lithium succinate</name>
      <description>Pramipexole may decrease the excretion rate of Lithium succinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Methyclothiazide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Pramipexole may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>Pramipexole may increase the excretion rate of Methazolamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>Pramipexole may increase the excretion rate of Conivaptan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Pramipexole may increase the excretion rate of Diclofenamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>Pramipexole may increase the excretion rate of Dapagliflozin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Pramipexole may increase the excretion rate of Torasemide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Pramipexole may increase the excretion rate of Chlorthalidone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Pramipexole may increase the excretion rate of Bendroflumethiazide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Pramipexole may increase the excretion rate of Cyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Pramipexole may increase the excretion rate of Eplerenone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Pramipexole may increase the excretion rate of Hydroflumethiazide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Pramipexole may increase the excretion rate of Chlorothiazide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Pramipexole may increase the excretion rate of Trichlormethiazide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Pramipexole may increase the excretion rate of Diazoxide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Pramipexole may increase the excretion rate of Polythiazide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>Pramipexole may increase the excretion rate of Tienilic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Pramipexole may increase the excretion rate of Efonidipine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>Pramipexole may increase the excretion rate of Cicletanine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Pramipexole may increase the excretion rate of Cyclopenthiazide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>Pramipexole may increase the excretion rate of Muzolimine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Pramipexole may increase the excretion rate of Xipamide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>Ethoxzolamide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Benzthiazide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Quinethazone may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Drospirenone may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>Theobromine may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Piretanide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05034</drugbank-id>
      <name>Ularitide</name>
      <description>Ularitide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>Tolvaptan may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>Indisulam may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>Azosemide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>Canrenoic acid may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>Potassium citrate may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>Isosorbide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>Ertugliflozin may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>Canrenone may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12670</drugbank-id>
      <name>Rolofylline</name>
      <description>Rolofylline may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12704</drugbank-id>
      <name>Spiradoline</name>
      <description>Spiradoline may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>Meticrane may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>Mefruside may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>Mebutizide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>Clorexolone may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>Clofenamide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>Fenquizone may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>Clopamide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Epitizide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>Bromotheophylline may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>Potassium may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>Amantadine may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The therapeutic efficacy of Valsartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The therapeutic efficacy of Ramipril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The therapeutic efficacy of Esmolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The therapeutic efficacy of Betaxolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>The therapeutic efficacy of Remikiren can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00217</drugbank-id>
      <name>Bethanidine</name>
      <description>The therapeutic efficacy of Bethanidine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00226</drugbank-id>
      <name>Guanadrel</name>
      <description>The therapeutic efficacy of Guanadrel can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The therapeutic efficacy of Olmesartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The therapeutic efficacy of Atenolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The therapeutic efficacy of Diltiazem can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>The therapeutic efficacy of Minoxidil can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The therapeutic efficacy of Treprostinil can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The therapeutic efficacy of Amlodipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The therapeutic efficacy of Nimodipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The therapeutic efficacy of Trandolapril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The therapeutic efficacy of Lercanidipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The therapeutic efficacy of Benazepril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The therapeutic efficacy of Bosentan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The therapeutic efficacy of Enalapril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>The therapeutic efficacy of Candoxatril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The therapeutic efficacy of Nicardipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The therapeutic efficacy of Guanabenz can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The therapeutic efficacy of Losartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The therapeutic efficacy of Moexipril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>The therapeutic efficacy of Nitroglycerin can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>The therapeutic efficacy of Metyrosine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00785</drugbank-id>
      <name>Cryptenamine</name>
      <description>The therapeutic efficacy of Cryptenamine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The therapeutic efficacy of Candesartan cilexetil can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>The therapeutic efficacy of Tolazoline can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The therapeutic efficacy of Eprosartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The therapeutic efficacy of Quinapril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The therapeutic efficacy of Omapatrilat can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The therapeutic efficacy of Felodipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The therapeutic efficacy of Irbesartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The therapeutic efficacy of Nitrendipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01089</drugbank-id>
      <name>Deserpidine</name>
      <description>The therapeutic efficacy of Deserpidine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Pentolinium can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Trimethaphan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The therapeutic efficacy of Carvedilol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The therapeutic efficacy of Bretylium can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The therapeutic efficacy of Terazosin can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The therapeutic efficacy of Rescinnamine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The therapeutic efficacy of Acebutolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The therapeutic efficacy of Captopril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The therapeutic efficacy of Bepridil can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The therapeutic efficacy of Bevantolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The therapeutic efficacy of Practolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The therapeutic efficacy of Cilazapril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>The therapeutic efficacy of Saprisartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The therapeutic efficacy of Spirapril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The therapeutic efficacy of Mibefradil can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The therapeutic efficacy of Dexpropranolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The therapeutic efficacy of Debrisoquine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The therapeutic efficacy of Celiprolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The therapeutic efficacy of Nebivolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The therapeutic efficacy of Sitaxentan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The therapeutic efficacy of Ambrisentan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>The therapeutic efficacy of Diethylnorspermine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The therapeutic efficacy of Nilvadipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06762</drugbank-id>
      <name>Pinacidil</name>
      <description>The therapeutic efficacy of Pinacidil can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The therapeutic efficacy of Ferulic acid can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The therapeutic efficacy of Bupranolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The therapeutic efficacy of Temocapril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The therapeutic efficacy of Riociguat can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>The therapeutic efficacy of Indoramin can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The therapeutic efficacy of Indenolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>The therapeutic efficacy of Aliskiren can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09206</drugbank-id>
      <name>Trimazosin</name>
      <description>The therapeutic efficacy of Trimazosin can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The therapeutic efficacy of Manidipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The therapeutic efficacy of Niguldipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>The therapeutic efficacy of Moxonidine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09363</drugbank-id>
      <name>Rauwolfia serpentina root</name>
      <description>The therapeutic efficacy of Rauwolfia serpentina root can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The therapeutic efficacy of Selexipag can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11720</drugbank-id>
      <name>Angiotensin 1-7</name>
      <description>The therapeutic efficacy of Angiotensin 1-7 can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11738</drugbank-id>
      <name>Rilmenidine</name>
      <description>The therapeutic efficacy of Rilmenidine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The therapeutic efficacy of Talinolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The therapeutic efficacy of Imidapril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12054</drugbank-id>
      <name>BQ-123</name>
      <description>The therapeutic efficacy of BQ-123 can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The therapeutic efficacy of Naftopidil can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The therapeutic efficacy of Landiolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The therapeutic efficacy of Dihydralazine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>The therapeutic efficacy of Zofenopril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13211</drugbank-id>
      <name>Guanoxan</name>
      <description>The therapeutic efficacy of Guanoxan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>The therapeutic efficacy of Delapril can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The therapeutic efficacy of Vincamine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The therapeutic efficacy of Linsidomine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13410</drugbank-id>
      <name>Guanoxabenz</name>
      <description>The therapeutic efficacy of Guanoxabenz can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13429</drugbank-id>
      <name>Tolonidine</name>
      <description>The therapeutic efficacy of Tolonidine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13435</drugbank-id>
      <name>Endralazine</name>
      <description>The therapeutic efficacy of Endralazine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The therapeutic efficacy of Esatenolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13452</drugbank-id>
      <name>Cadralazine</name>
      <description>The therapeutic efficacy of Cadralazine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The therapeutic efficacy of Cloranolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13575</drugbank-id>
      <name>Bietaserpine</name>
      <description>The therapeutic efficacy of Bietaserpine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13604</drugbank-id>
      <name>Guanazodine</name>
      <description>The therapeutic efficacy of Guanazodine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13631</drugbank-id>
      <name>Methoserpidine</name>
      <description>The therapeutic efficacy of Methoserpidine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The therapeutic efficacy of Epanolol can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13779</drugbank-id>
      <name>Guanoclor</name>
      <description>The therapeutic efficacy of Guanoclor can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The therapeutic efficacy of Candesartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The therapeutic efficacy of Dexniguldipine can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The therapeutic efficacy of Tocopherylquinone can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>The therapeutic efficacy of Benazeprilat can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>The therapeutic efficacy of Fosinoprilat can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>The therapeutic efficacy of Ramiprilat can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>The therapeutic efficacy of Perindoprilat can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>The therapeutic efficacy of Quinaprilat can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>The risk or severity of adverse effects can be decreased when Pramipexole is combined with Fenoldopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09097</drugbank-id>
      <name>Quinagolide</name>
      <description>The risk or severity of adverse effects can be decreased when Pramipexole is combined with Quinagolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>The risk or severity of adverse effects can be decreased when Pramipexole is combined with Dihydroergocornine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12313</drugbank-id>
      <name>Dopexamine</name>
      <description>The risk or severity of adverse effects can be decreased when Pramipexole is combined with Dopexamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12478</drugbank-id>
      <name>Piribedil</name>
      <description>The risk or severity of adverse effects can be decreased when Pramipexole is combined with Piribedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12890</drugbank-id>
      <name>Dihydrexidine</name>
      <description>The risk or severity of adverse effects can be decreased when Pramipexole is combined with Dihydrexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>The risk or severity of adverse effects can be decreased when Pramipexole is combined with Ibopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>The risk or severity of adverse effects can be decreased when Pramipexole is combined with Dihydroergocryptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06077</drugbank-id>
      <name>Lumateperone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Lumateperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Methylergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Thiethylperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Sulpiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Remoxipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Prochlorperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Droperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Buspirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Lisuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Mesoridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01038</drugbank-id>
      <name>Carphenazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Carphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Acetophenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01425</drugbank-id>
      <name>Alizapride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Alizapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Molindone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06109</drugbank-id>
      <name>YKP-1358</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with YKP-1358.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09018</drugbank-id>
      <name>Bromopride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Bromopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09207</drugbank-id>
      <name>AS-8112</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with AS-8112.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Blonanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12579</drugbank-id>
      <name>JNJ-37822681</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with JNJ-37822681.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13511</drugbank-id>
      <name>Clebopride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Clebopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15167</drugbank-id>
      <name>Fallypride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Fallypride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15492</drugbank-id>
      <name>Eticlopride</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Eticlopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The risk or severity of adverse effects can be increased when Nelfinavir is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The risk or severity of adverse effects can be increased when Indinavir is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The risk or severity of adverse effects can be increased when Nevirapine is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The risk or severity of adverse effects can be increased when Prazosin is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The risk or severity of adverse effects can be increased when Doxazosin is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The risk or severity of adverse effects can be increased when Verapamil is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The risk or severity of adverse effects can be increased when Ganciclovir is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The risk or severity of adverse effects can be increased when Saquinavir is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The risk or severity of adverse effects can be increased when Palbociclib is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The risk or severity of adverse effects can be increased when Pitolisant is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The risk or severity of adverse effects can be increased when Dacomitinib is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The risk or severity of adverse effects can be increased when Gilteritinib is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The risk or severity of adverse effects can be increased when Rucaparib is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00122</drugbank-id>
      <name>Choline</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Choline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00152</drugbank-id>
      <name>Thiamine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Thiamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Metformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00345</drugbank-id>
      <name>Aminohippuric acid</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Aminohippuric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Norepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00536</drugbank-id>
      <name>Guanidine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Guanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Amiloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Clopidogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Estradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Phenformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Dinoprostone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Phenoxybenzamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Famotidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Dopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01103</drugbank-id>
      <name>Quinacrine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Quinacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Varenicline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03034</drugbank-id>
      <name>D-Levofloxacin</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with D-Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05381</drugbank-id>
      <name>Histamine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Histamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05383</drugbank-id>
      <name>Pimagedine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Pimagedine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06608</drugbank-id>
      <name>Tafenoquine</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Dolutegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09555</drugbank-id>
      <name>Dexchlorpheniramine maleate</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Dexchlorpheniramine maleate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Isavuconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Estradiol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Estradiol benzoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Estradiol cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Estradiol dienanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Estradiol valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Choline salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Dronedarone.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.18</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.40e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>pramipexole</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>211.327</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>211.114318249</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCN[C@H]1CCC2=C(C1)SC(N)=N2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C10H17N3S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>FASDKYOPVNHBLU-ZETCQYMHSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>50.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>59.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>24.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>17.66</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>10.31</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>freely soluble in water</value>
      <source>https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022421s000ChemR.pdf</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>288-290</value>
      <source>https://www.chemicalbook.com/ChemicalProductProperty_US_CB0486178.aspx</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>378</value>
      <source>https://www.lookchem.com/Pramipexole/</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.42</value>
      <source>https://pdf.hres.ca/dpd_pm/00043389.PDF</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.2</value>
      <source>http://www.t3db.ca/toxins/T3D2783</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>5.6, 9.5</value>
      <source>https://pdf.hres.ca/dpd_pm/00043389.PDF</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11733</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>8356</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>119570</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505897</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00559</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>106770</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50116766</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164742949</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000019</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>953</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>953</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Pramipexole</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL301265</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/prampex.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mir1271.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/pramipexole.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000581</id>
      <name>Dopamine D3 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A176873</ref-id>
            <pubmed-id>18248314</pubmed-id>
            <citation>Merlino G, Serafini A, Robiony F, Valente M, Gigli GL: Clinical experience with pramipexole in the treatment of restless legs syndrome. Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):225-35. doi: 10.1517/17425255.4.2.225.</citation>
          </article>
          <article>
            <ref-id>A176909</ref-id>
            <pubmed-id>9617505</pubmed-id>
            <citation>Piercey MF: Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.</citation>
          </article>
          <article>
            <ref-id>A176912</ref-id>
            <pubmed-id>22023785</pubmed-id>
            <citation>Chernoloz O, El Mansari M, Blier P: Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J Psychiatry Neurosci. 2012 Feb;37(2):113-21. doi: 10.1503/jpn.110038.</citation>
          </article>
          <article>
            <ref-id>A176915</ref-id>
            <pubmed-id>9638397</pubmed-id>
            <citation>Dooley M, Markham A: Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging. 1998 Jun;12(6):495-514. doi: 10.2165/00002512-199812060-00007.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35462" source="Swiss-Prot">
        <name>D(3) dopamine receptor</name>
        <general-function>G-protein coupled amine receptor activity</general-function>
        <specific-function>Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.</specific-function>
        <gene-name>DRD3</gene-name>
        <locus>3q13.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>33-55
66-88
105-126
150-170
188-212
330-351
367-388</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.07</theoretical-pi>
        <molecular-weight>44224.335</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3024</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DRD3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U32499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>927342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>216</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>216</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35462</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRD3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Dopamine D3 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001159|D(3) dopamine receptor
MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERAL
QTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILN
LCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTV
CSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQ
QTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRK
LSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHV
SPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021269|D(3) dopamine receptor (DRD3)
ATGGCATCTCTGAGCCAGCTGAGTGGCCACCTGAACTACACCTGTGGGGCAGAGAACTCC
ACAGGTGCCAGCCAGGCCCGCCCACATGCCTACTATGCCCTCTCCTACTGCGCGCTCATC
CTGGCCATCGTCTTCGGCAATGGCCTGGTGTGCATGGCTGTGCTGAAGGAGCGGGCCCTG
CAGACTACCACCAACTACTTAGTAGTGAGCCTGGCTGTGGCAGACTTGCTGGTGGCCACC
TTGGTGATGCCCTGGGTGGTATACCTGGAGGTGACAGGTGGAGTCTGGAATTTCAGCCGC
ATTTGCTGTGATGTTTTTGTCACCCTGGATGTCATGATGTGTACAGCCAGCATCCTTAAT
CTCTGTGCCATCAGCATAGACAGGTACACTGCAGTGGTCATGCCCGTTCACTACCAGCAT
GGCACGGGACAGAGCTCCTGTCGGCGCGTGGCCCTCATGATCACGGCCGTCTGGGTACTG
GCCTTTGCTGTGTCCTGCCCTCTTCTGTTTGGCTTTAATACCACAGGGGACCCCACTGTC
TGCTCCATCTCCAACCCTGATTTTGTCATCTACTCTTCAGTGGTGTCCTTCTACCTGCCC
TTTGGAGTGACTGTCCTTGTCTATGCCAGAATCTATGTGGTGCTGAAACAAAGGAGACGG
AAAAGGATCCTCACTCGACAGAACAGTCAGTGCAACAGTGTCAGGCCTGGCTTCCCCCAA
CAAACCCTCTCTCCTGACCCGGCACATCTGGAGCTGAAGCGTTACTACAGCATCTGCCAG
GACACTGCCTTGGGTGGACCAGGCTTCCAAGAAAGAGGAGGAGAGTTGAAAAGAGAGGAG
AAGACTCGGAATTCCCTGAGTCCCACCATAGCGCCCAAGCTCAGCTTAGAAGTTCGAAAA
CTCAGCAATGGCAGATTATCGACATCTTTGAAGCTGGGGCCCCTGCAACCTCGGGGAGTG
CCACTTCGGGAGAAGAAGGCAACCCAAATGGTGGCCATTGTGCTTGGGGCCTTCATTGTC
TGCTGGCTGCCCTTCTTCTTGACCCATGTTCTCAATACCCACTGCCAGACATGCCACGTG
TCCCCAGAGCTTTACAGTGCCACGACATGGCTGGGCTACGTGAATAGCGCCCTCAACCCT
GTGATCTATACCACCTTCAATATCGAGTTCCGGAAAGCCTTCCTCAAGATCCTGTCTTGC
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled amine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gastric emptying</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning or memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>musculoskeletal movement, spinal reflex action</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of oligodendrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sodium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokinesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of renal sodium excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood volume by renin-angiotensin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian sleep/wake cycle, sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion involved in locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000756</id>
      <name>Dopamine D2 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A176909</ref-id>
            <pubmed-id>9617505</pubmed-id>
            <citation>Piercey MF: Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.</citation>
          </article>
          <article>
            <ref-id>A176912</ref-id>
            <pubmed-id>22023785</pubmed-id>
            <citation>Chernoloz O, El Mansari M, Blier P: Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J Psychiatry Neurosci. 2012 Feb;37(2):113-21. doi: 10.1503/jpn.110038.</citation>
          </article>
          <article>
            <ref-id>A176915</ref-id>
            <pubmed-id>9638397</pubmed-id>
            <citation>Dooley M, Markham A: Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging. 1998 Jun;12(6):495-514. doi: 10.2165/00002512-199812060-00007.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14416" source="Swiss-Prot">
        <name>D(2) dopamine receptor</name>
        <general-function>Potassium channel regulator activity</general-function>
        <specific-function>Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.</specific-function>
        <gene-name>DRD2</gene-name>
        <locus>11q23</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>38-60
71-93
109-130
152-172
189-213
374-395
410-431</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.85</theoretical-pi>
        <molecular-weight>50618.91</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3023</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DRD2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M30625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181432</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>215</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>215</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P14416</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRD2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Dopamine D2 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001508|D(2) dopamine receptor
MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVFGNVLVCMAVS
REKALQTTTNYLIVSLAVADLLVATLVMPWVVYLEVVGEWKFSRIHCDIFVTLDVMMCTA
SILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNNADQN
ECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTKRSSRAFRAHLRAPL
KGNCTHPEDMKLCTVIMKSNGSFPVNRRRVEAARRAQELEMEMLSSTSPPERTRYSPIPP
SHHQLTLPDPSHHGLHSTPDSPAKPEKNGHAKDHPKIAKIFEIQTMPNGKTRTSLKTMSR
RKLSQQKEKKATQMLAIVLGVFIICWLPFFITHILNIHCDCNIPPVLYSAFTWLGYVNSA
VNPIIYTTFNIEFRKAFLKILHC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021274|D(2) dopamine receptor (DRD2)
ATGGATCCACTGAATCTGTCCTGGTATGATGATGATCTGGAGAGGCAGAACTGGAGCCGG
CCCTTCAACGGGTCAGACGGGAAGGCGGACAGACCCCACTACAACTACTATGCCACACTG
CTCACCCTGCTCATCGCTGTCATCGTCTTCGGCAACGTGCTGGTGTGCATGGCTGTGTCC
CGCGAGAAGGCGCTGCAGACCACCACCAACTACCTGATCGTCAGCCTCGCAGTGGCCGAC
CTCCTCGTCGCCACACTGGTCATGCCCTGGGTTGTCTACCTGGAGGTGGTAGGTGAGTGG
AAATTCAGCAGGATTCACTGTGACATCTTCGTCACTCTGGACGTCATGATGTGCACGGCG
AGCATCCTGAACTTGTGTGCCATCAGCATCGACAGGTACACAGCTGTGGCCATGCCCATG
CTGTACAATACGCGCTACAGCTCCAAGCGCCGGGTCACCGTCATGATCTCCATCGTCTGG
GTCCTGTCCTTCACCATCTCCTGCCCACTCCTCTTCGGACTCAATAACGCAGACCAGAAC
GAGTGCATCATTGCCAACCCGGCCTTCGTGGTCTACTCCTCCATCGTCTCCTTCTACGTG
CCCTTCATTGTCACCCTGCTGGTCTACATCAAGATCTACATTGTCCTCCGCAGACGCCGC
AAGCGAGTCAACACCAAACGCAGCAGCCGAGCTTTCAGGGCCCACCTGAGGGCTCCACTA
AAGGGCAACTGTACTCACCCCGAGGACATGAAACTCTGCACCGTTATCATGAAGTCTAAT
GGGAGTTTCCCAGTGAACAGGCGGAGAGTGGAGGCTGCCCGGCGAGCCCAGGAGCTGGAG
ATGGAGATGCTCTCCAGCACCAGCCCACCCGAGAGGACCCGGTACAGCCCCATCCCACCC
AGCCACCACCAGCTGACTCTCCCCGACCCGTCCCACCATGGTCTCCACAGCACTCCCGAC
AGCCCCGCCAAACCAGAGAAGAATGGGCATGCCAAAGACCACCCCAAGATTGCCAAGATC
TTTGAGATCCAGACCATGCCCAATGGCAAAACCCGGACCTCCCTCAAGACCATGAGCCGT
AGGAAGCTCTCCCAGCAGAAGGAGAAGAAAGCCACTCAGATGCTCGCCATTGTTCTCGGC
GTGTTCATCATCTGCTGGCTGCCCTTCTTCATCACACACATCCTGAACATACACTGTGAC
TGCAACATCCCGCCTGTCCTGTACAGCGCCTTCACGTGGCTGGGCTATGTCAACAGCGCC
GTGAACCCCATCATCTACACCACCTTCAACATTGAGTTCCGCAAGGCCTTCCTGAAGATC
CTCCACTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acrosomal vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ciliary membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nonmotile primary cilium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sperm flagellum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>potassium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenohypophysis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult walking behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>associative learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>auditory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>branching morphogenesis of a nerve</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebral cortex GABAergic interneuron migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>grooming behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-term memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of circadian sleep/wake cycle, sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron-neuron synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>orbitofrontal cortex development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peristalsis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pigmentation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokinesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G-protein coupled receptor protein signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glial cell-derived neurotrophic factor secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of growth hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of long-term synaptic potentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuroblast proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of renal sodium excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of urine volume</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion involved in locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of long-term neuronal synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of phosphoprotein phosphatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synapse structural plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to axon injury</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to inactivity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to iron ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to light stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of smell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>striatum development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synapse assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Wnt signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000389</id>
      <name>Dopamine D4 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A176909</ref-id>
            <pubmed-id>9617505</pubmed-id>
            <citation>Piercey MF: Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.</citation>
          </article>
          <article>
            <ref-id>A176915</ref-id>
            <pubmed-id>9638397</pubmed-id>
            <citation>Dooley M, Markham A: Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging. 1998 Jun;12(6):495-514. doi: 10.2165/00002512-199812060-00007.</citation>
          </article>
          <article>
            <ref-id>A618</ref-id>
            <pubmed-id>7664822</pubmed-id>
            <citation>Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P21917" source="Swiss-Prot">
        <name>D(4) dopamine receptor</name>
        <general-function>Sh3 domain binding</general-function>
        <specific-function>Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).</specific-function>
        <gene-name>DRD4</gene-name>
        <locus>11p15.5</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>38-60
71-93
110-131
152-175
192-213
395-417
427-449</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.37</theoretical-pi>
        <molecular-weight>48359.86</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3025</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DRD4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L12398</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>291946</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>217</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>217</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21917</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRD4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>D(2C) dopamine receptor</synonym>
          <synonym>Dopamine D4 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000775|D(4) dopamine receptor
MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLAGNSLVCVSVA
TERALQTPTNSFIVSLAAADLLLALLVLPLFVYSEVQGGAWLLSPRLCDALMAMDVMLCT
ASIFNLCAISVDRFVAVAVPLRYNRQGGSRRQLLLIGATWLLSAAVAAPVLCGLNDVRGR
DPAVCRLEDRDYVVYSSVCSFFLPCPLMLLLYWATFRGLQRWEVARRAKLHGRAPRRPSG
PGPPSPTPPAPRLPQDPCGPDCAPPAPGLPRGPCGPDCAPAAPGLPPDPCGPDCAPPAPG
LPQDPCGPDCAPPAPGLPRGPCGPDCAPPAPGLPQDPCGPDCAPPAPGLPPDPCGSNCAP
PDAVRAAALPPQTPPQTRRRRRAKITGRERKAMRVLPVVVGAFLLCWTPFFVVHITQALC
PACSVPPRLVSAVTWLGYVNSALNPVIYTVFNAEFRNVFRKALRACC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010271|D(4) dopamine receptor (DRD4)
ATGGGGAACCGCAGCACCGCGGACGCGGACGGGCTGCTGGCTGGGCGCGGGCCGGCCGCG
GGGGCATCTGCGGGGGCATCTGCGGGGCTGGCTGGGCAGGGCGCGGCGGCGCTGGTGGGG
GGCGTGCTGCTCATCGGCGCGGTGCTCGCGGGGAACTCGCTCGTGTGCGTGAGCGTGGCC
ACCGAGCGCGCCCTGCAGACGCCCACCAACTCCTTCATCGTGAGCCTGGCGGCCGCCGAC
CTCCTCCTCGCTCTCCTGGTGCTGCCGCTCTTCGTCTACTCCGAGGTCCAGGGTGGCGCG
TGGCTGCTGAGCCCCCGCCTGTGCGACGCCCTCATGGCCATGGACGTCATGCTGTGCACC
GCCTCCATCTTCAACCTGTGCGCCATCAGCGTGGACAGGTTCGTGGCCGTGGCCGTGCCG
CTGCGCTACAACCGGCAGGGTGGGAGCCGCCGGCAGCTGCTGCTCATCGGCGCCACGTGG
CTGCTGTCCGCGGCGGTGGCGGCGCCCGTACTGTGCGGCCTCAACGACGTGCGCGGCCGC
GACCCCGCCGTGTGCCGCCTGGAGGACCGCGACTACGTGGTCTACTCGTCCGTGTGCTCC
TTCTTCCTACCCTGCCCGCTCATGCTGCTGCTCTACTGGGCCACGTTCCGCGGCCTGCAG
CGCTGGGAGGTGGCACGTCGCGCCAAGCTGCACGGCCGCGCGCCCCGCCGACCCAGCGGC
CCTGGCCCGCCTTCCCCCACGCCACCCGCGCCCCGCCTCCCCCAGGACCCCTGCGGCCCC
GACTGTGCGCCCCCCGCGCCCGGCCTTCCCCGGGGTCCCTGCGGCCCCGACTGTGCGCCC
GCCGCGCCCAGCCTCCCCCAGGACCCCTGCGGCCCCGACTGTGCGCCCCCCGCGCCCGGC
CTCCCCCCGGACCCCTGCGGCTCCAACTGTGCTCCCCCCGACGCCGTCAGAGCCGCCGCG
CTCCCACCCCAGACTCCACCGCAGACCCGCAGGAGGCGGCGTGCCAAGATCACCGGCCGG
GAGCGCAAGGCCATGAGGGTCCTGCCGGTGGTGGTCGGGGCCTTCCTGCTGTGCTGGACG
CCCTTCTTCGTGGTGCACATCACGCAGGCGCTGTGTCCTGCCTGCTCCGTGCCCCCGCGG
CTGGTCAGCGCCGTCACCTGGCTGGGCTACGTCAACAGCGCCCTCAACCCCGTCATCTAC
ACTGTCTTCAACGCCGAGTTCCGCAACGTCTTCCGCAAGGCCCTGCGTGCCTGCTGCTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell cortex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal bouton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled amine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>potassium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>SH3 domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inhibitory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>olfactory learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>photoperiodism</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of penile erection</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sodium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of neurotransmitter secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to steroid hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>short-term memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000291</id>
      <name>5-hydroxytryptamine receptor 1A</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A176912</ref-id>
            <pubmed-id>22023785</pubmed-id>
            <citation>Chernoloz O, El Mansari M, Blier P: Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J Psychiatry Neurosci. 2012 Feb;37(2):113-21. doi: 10.1503/jpn.110038.</citation>
          </article>
          <article>
            <ref-id>A176927</ref-id>
            <pubmed-id>18688211</pubmed-id>
            <citation>Chernoloz O, El Mansari M, Blier P: Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology. 2009 Feb;34(3):651-61. doi: 10.1038/npp.2008.114. Epub 2008 Aug 6.</citation>
          </article>
          <article>
            <ref-id>A6309</ref-id>
            <pubmed-id>16963794</pubmed-id>
            <citation>Rogoz Z, Skuza G: Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol Rep. 2006 Jul-Aug;58(4):493-500.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08908" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 1A</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.</specific-function>
        <gene-name>HTR1A</gene-name>
        <locus>5q11.2-q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>37-62
74-98
111-132
153-178
192-217
346-367
379-403</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.05</theoretical-pi>
        <molecular-weight>46106.335</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5286</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR1A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M28269</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189928</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08908</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT1A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-1A</synonym>
          <synonym>ADRB2RL1</synonym>
          <synonym>ADRBRL1</synonym>
          <synonym>G-21</synonym>
          <synonym>Serotonin receptor 1A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018934|5-hydroxytryptamine receptor 1A
MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAA
IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCC
TSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED
RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT
RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGN
SKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLP
FFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFC
RQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018935|5-hydroxytryptamine receptor 1A (HTR1A)
ATGGATGTGCTCAGCCCTGGTCAGGGCAACAACACCACATCACCACCGGCTCCCTTTGAG
ACCGGCGGCAACACTACTGGTATCTCCGACGTGACCGTCAGCTACCAAGTGATCACCTCT
CTGCTGCTGGGCACGCTCATCTTCTGCGCGGTGCTGGGCAATGCGTGCGTGGTGGCTGCC
ATCGCCTTGGAGCGCTCCCTGCAGAACGTGGCCAATTATCTTATTGGCTCTTTGGCGGTC
ACCGACCTCATGGTGTCGGTGTTGGTGCTGCCCATGGCCGCGCTGTATCAGGTGCTCAAC
AAGTGGACACTGGGCCAGGTAACCTGCGACCTGTTCATCGCCCTCGACGTGCTGTGCTGC
ACCTCATCCATCTTGCACCTGTGCGCCATCGCGCTGGACAGGTACTGGGCCATCACGGAC
CCCATCGACTACGTGAACAAGAGGACGCCCCGGCGCGCCGCTGCGCTCATCTCGCTCACT
TGGCTTATTGGCTTCCTCATCTCTATCCCGCCCATGCTGGGCTGGCGCACCCCGGAAGAC
CGCTCGGACCCCGACGCATGCACCATTAGCAAGGATCATGGCTACACTATCTATTCCACC
TTTGGAGCTTTCTACATCCCGCTGCTGCTCATGCTGGTTCTCTATGGGCGCATATTCCGA
GCTGCGCGCTTCCGCATCCGCAAGACGGTCAAAAAGGTGGAGAAGACCGGAGCGGACACC
CGCCATGGAGCATCTCCCGCCCCGCAGCCCAAGAAGAGTGTGAATGGAGAGTCGGGGAGC
AGGAACTGGAGGCTGGGCGTGGAGAGCAAGGCTGGGGGTGCTCTGTGCGCCAATGGCGCG
GTGAGGCAAGGTGACGATGGCGCCGCCCTGGAGGTGATCGAGGTGCACCGAGTGGGCAAC
TCCAAAGAGCACTTGCCTCTGCCCAGCGAGGCTGGTCCTACCCCTTGTGCCCCCGCCTCT
TTCGAGAGGAAAAATGAGCGCAACGCCGAGGCGAAGCGCAAGATGGCCCTGGCCCGAGAG
AGGAAGACAGTGAAGACGCTGGGCATCATCATGGGCACCTTCATCCTCTGCTGGCTGCCC
TTCTTCATCGTGGCTCTTGTTCTGCCCTTCTGCGAGAGCAGCTGCCACATGCCCACCCTG
TTGGGCGCCATAATCAATTGGCTGGGCTACTCCAACTCTCTGCTTAACCCCGTCATTTAC
GCATACTTCAACAAGGACTTTCAAAACGCGTTTAAGAAGATCATTAAGTGTAAGTTCTGC
CGCCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exploration behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of serotonin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000289</id>
      <name>Alpha-2A adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A2080</ref-id>
            <pubmed-id>18691132</pubmed-id>
            <citation>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.</citation>
          </article>
          <article>
            <ref-id>A15316</ref-id>
            <pubmed-id>12388667</pubmed-id>
            <citation>Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14.</citation>
          </article>
          <article>
            <ref-id>A176924</ref-id>
            <pubmed-id>30363854</pubmed-id>
            <citation>Apraxine M, Pasquet A, Jeanjean A: Pramipexole-Induced Reversible Heart Failure. Mov Disord Clin Pract. 2014 Oct 23;1(4):381-382. doi: 10.1002/mdc3.12096. eCollection 2014 Dec.</citation>
          </article>
          <article>
            <ref-id>A176921</ref-id>
            <pubmed-id>26976325</pubmed-id>
            <citation>McCormick PN, Fletcher PJ, Wilson VS, Remington GJ: The adrenergic alpha2 antagonist atipamezole alters the behavioural effects of pramipexole and increases pramipexole concentration in blood plasma. Life Sci. 2016 Apr 15;151:300-304. doi: 10.1016/j.lfs.2016.03.017. Epub 2016 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L5885</ref-id>
            <title>Zhang Lab, University of Michigan document</title>
            <url>https://zhanglab.ccmb.med.umich.edu/GLASS/assoc.cgi?id=73750</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08913" source="Swiss-Prot">
        <name>Alpha-2A adrenergic receptor</name>
        <general-function>Thioesterase binding</general-function>
        <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline &gt; clonidine &gt; epinephrine &gt; norepinephrine &gt; phenylephrine &gt; dopamine &gt; p-synephrine &gt; p-tyramine &gt; serotonin = p-octopamine. For antagonists, the rank order is yohimbine &gt; phentolamine = mianserine &gt; chlorpromazine = spiperone = prazosin &gt; propanolol &gt; alprenolol = pindolol.</specific-function>
        <gene-name>ADRA2A</gene-name>
        <locus>10q24-q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>34-59
71-96
107-129
152-172
195-217
375-395
410-429</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.2</theoretical-pi>
        <molecular-weight>48956.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:281</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M23533</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178196</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>25</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>25</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08913</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA2A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA2R</synonym>
          <synonym>ADRAR</synonym>
          <synonym>Alpha-2 adrenergic receptor subtype C10</synonym>
          <synonym>Alpha-2A adrenoceptor</synonym>
          <synonym>Alpha-2A adrenoreceptor</synonym>
          <synonym>Alpha-2AAR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021255|Alpha-2A adrenergic receptor
MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT
SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS
IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG
PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA
APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD
HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS
RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS
LNPVIYTIFNHDFRRAFKKILCRGDRKRIV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021256|Alpha-2A adrenergic receptor (ADRA2A)
ATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG
CCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCC
ACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTG
CTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAG
GCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTC
GTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGG
TGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGC
GCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGC
ACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCC
TTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAG
CCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTC
TTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGT
CGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGC
ACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAG
GCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCG
CGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCT
CCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAG
GTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCG
GCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGG
CAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTG
TGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGC
ACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATC
TACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGAC
AGGAAGCGGATCGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-1B adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-2C adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heterotrimeric G-protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thioesterase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>actin cytoskeleton organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal absorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>movement of cell or subcellular component</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion-dependent exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of uterine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epidermal growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of membrane protein ectodomain proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of wound healing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Rho protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thermoception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="7">
      <id>BE0003647</id>
      <name>Solute carrier family 22 member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16033</ref-id>
            <pubmed-id>15640376</pubmed-id>
            <citation>Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I: Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005 Apr;33(4):495-9. Epub 2005 Jan 7.</citation>
          </article>
          <article>
            <ref-id>A39849</ref-id>
            <pubmed-id>20496886</pubmed-id>
            <citation>Diao L, Shu Y, Polli JE: Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7. doi: 10.1021/mp100036b.</citation>
          </article>
          <article>
            <ref-id>A176936</ref-id>
            <pubmed-id>26360835</pubmed-id>
            <citation>Knop J, Hoier E, Ebner T, Fromm MF, Muller F: Renal tubular secretion of pramipexole. Eur J Pharm Sci. 2015 Nov 15;79:73-8. doi: 10.1016/j.ejps.2015.09.004. Epub 2015 Sep 7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15244" source="Swiss-Prot">
        <name>Solute carrier family 22 member 2</name>
        <general-function>Quaternary ammonium group transmembrane transporter activity</general-function>
        <specific-function>Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.</specific-function>
        <gene-name>SLC22A2</gene-name>
        <locus>6q26</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>23-43
151-171
178-198
209-229
239-259
264-284
349-369
376-396
415-435
442-462
465-485
495-515</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.45</theoretical-pi>
        <molecular-weight>62579.99</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10966</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X98333</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2281942</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1020</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15244</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOCT2</synonym>
          <synonym>OCT2</synonym>
          <synonym>Organic cation transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037250|Solute carrier family 22 member 2
MPTTVDDVLEHGGEFHFFQKQMFFLLALLSATFAPIYVGIVFLGFTPDHRCRSPGVAELS
LRCGWSPAEELNYTVPGPGPAGEASPRQCRRYEVDWNQSTFDCVDPLASLDTNRSRLPLG
PCRDGWVYETPGSSIVTEFNLVCANSWMLDLFQSSVNVGFFIGSMSIGYIADRFGRKLCL
LTTVLINAAAGVLMAISPTYTWMLIFRLIQGLVSKAGWLIGYILITEFVGRRYRRTVGIF
YQVAYTVGLLVLAGVAYALPHWRWLQFTVSLPNFFFLLYYWCIPESPRWLISQNKNAEAM
RIIKHIAKKNGKSLPASLQRLRLEEETGKKLNPSFLDLVRTPQIRKHTMILMYNWFTSSV
LYQGLIMHMGLAGDNIYLDFFYSALVEFPAAFMIILTIDRIGRRYPWAASNMVAGAACLA
SVFIPGDLQWLKIIISCLGRMGITMAYEIVCLVNAELYPTFIRNLGVHICSSMCDIGGII
TPFLVYRLTNIWLELPLMVFGVLGLVAGGLVLLLPETKGKALPETIEEAENMQRPRKNKE
KMIYLQVQKLDIPLN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012536|Solute carrier family 22 member 2 (SLC22A2)
ATGCCCACCACCGTGGACGATGTCCTGGAGCATGGAGGGGAGTTTCACTTTTTCCAGAAG
CAAATGTTTTTCCTCTTGGCTCTGCTCTCGGCTACCTTCGCGCCCATCTACGTGGGCATC
GTCTTCCTGGGCTTCACCCCTGACCACCGCTGCCGGAGCCCCGGAGTGGCCGAGCTGAGT
CTGCGCTGCGGCTGGAGTCCTGCAGAGGAACTGAACTACACGGTGCCGGGCCCAGGACCT
GCGGGCGAAGCCTCCCCAAGACAGTGTAGGCGCTACGAGGTGGACTGGAACCAGAGCACC
TTCGACTGCGTGGACCCCCTGGCCAGCCTGGACACCAACAGGAGCCGCCTGCCACTGGGC
CCCTGCCGGGACGGCTGGGTGTACGAGACGCCTGGCTCGTCCATCGTCACCGAGTTTAAC
CTGGTATGTGCCAACTCCTGGATGTTGGACCTATTCCAGTCATCAGTGAATGTAGGATTC
TTTATTGGCTCTATGAGTATCGGCTACATAGCAGACAGGTTTGGCCGTAAGCTCTGCCTC
CTAACTACAGTCCTCATAAATGCTGCAGCTGGAGTTCTCATGGCCATTTCCCCAACCTAT
ACGTGGATGTTAATTTTTCGCTTAATCCAAGGACTGGTCAGCAAAGCAGGCTGGTTAATA
GGCTACATCCTGATTACAGAATTTGTTGGGCGGAGATATCGGAGAACAGTGGGGATTTTT
TACCAAGTTGCCTATACAGTTGGGCTCCTGGTGCTAGCTGGGGTGGCTTACGCACTTCCT
CACTGGAGGTGGTTGCAGTTCACAGTTTCTCTGCCCAACTTCTTCTTCTTGCTCTATTAC
TGGTGCATACCTGAGTCTCCCAGGTGGCTGATCTCCCAGAATAAGAATGCTGAAGCCATG
AGAATCATTAAGCACATCGCAAAGAAAAATGGAAAATCTCTACCCGCCTCCCTTCAGCGC
CTGAGACTTGAAGAGGAAACTGGCAAGAAATTGAACCCTTCATTTCTTGACTTGGTCAGA
ACTCCTCAGATAAGGAAACATACTATGATATTGATGTACAACTGGTTCACGAGCTCTGTG
CTCTACCAGGGCCTCATCATGCACATGGGCCTTGCAGGTGACAATATCTACCTGGATTTC
TTCTACTCTGCCCTGGTTGAATTCCCAGCTGCCTTCATGATCATCCTCACCATCGACCGC
ATCGGACGCCGTTACCCTTGGGCTGCATCAAATATGGTTGCAGGGGCAGCCTGTCTGGCC
TCAGTTTTTATACCTGGTGATCTACAATGGCTAAAAATTATTATCTCATGCTTGGGAAGA
ATGGGGATCACAATGGCCTATGAGATAGTCTGCCTGGTCAATGCTGAGCTGTACCCCACA
TTCATTAGGAATCTTGGCGTCCACATCTGTTCCTCAATGTGTGACATTGGTGGCATCATC
ACGCCATTCCTGGTCTACCGGCTCACTAACATCTGGCTTGAGCTCCCGCTGATGGTTTTC
GGCGTGCTTGGCTTGGTTGCTGGAGGTCTGGTGCTGTTGCTTCCAGAAACTAAAGGGAAA
GCTTTGCCTGAGACCATCGAGGAAGCCGAAAATATGCAAAGACCAAGAAAAAATAAAGAA
AAGATGATTTACCTCCAAGTTCAGAAACTAGACATTCCATTGAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>choline transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic cation transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quaternary ammonium group transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ammonium transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>body fluid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>choline transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quaternary ammonium group transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="7">
      <id>BE0003648</id>
      <name>Solute carrier family 22 member 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16033</ref-id>
            <pubmed-id>15640376</pubmed-id>
            <citation>Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I: Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005 Apr;33(4):495-9. Epub 2005 Jan 7.</citation>
          </article>
          <article>
            <ref-id>A39849</ref-id>
            <pubmed-id>20496886</pubmed-id>
            <citation>Diao L, Shu Y, Polli JE: Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7. doi: 10.1021/mp100036b.</citation>
          </article>
          <article>
            <ref-id>A176933</ref-id>
            <pubmed-id>21654875</pubmed-id>
            <citation>Antonini A, Calandrella D: Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. Neuropsychiatr Dis Treat. 2011;7:297-302. doi: 10.2147/NDT.S10097. Epub 2011 May 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15245" source="Swiss-Prot">
        <name>Solute carrier family 22 member 1</name>
        <general-function>Secondary active organic cation transmembrane transporter activity</general-function>
        <specific-function>Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine, and metformin. The transport of organic cations is inhibited by a broad array of compounds like tetramethylammonium (TMA), cocaine, lidocaine, NMDA receptor antagonists, atropine, prazosin, cimetidine, TEA and NMN, guanidine, cimetidine, choline, procainamide, quinine, tetrabutylammonium, and tetrapentylammonium. Translocates organic cations in an electrogenic and pH-independent manner. Translocates organic cations across the plasma membrane in both directions. Transports the polyamines spermine and spermidine. Transports pramipexole across the basolateral membrane of the proximal tubular epithelial cells. The choline transport is activated by MMTS. Regulated by various intracellular signaling pathways including inhibition by protein kinase A activation, and endogenously activation by the calmodulin complex, the calmodulin-dependent kinase II and LCK tyrosine kinase.</specific-function>
        <gene-name>SLC22A1</gene-name>
        <locus>6q26</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>22-42
150-170
177-197
207-229
236-256
263-283
348-368
377-397
403-423
432-452
465-485
493-513</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.81</theoretical-pi>
        <molecular-weight>61153.345</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10963</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X98332</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2511670</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1019</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15245</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOCT1</synonym>
          <synonym>OCT1</synonym>
          <synonym>Organic cation transporter 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037862|Solute carrier family 22 member 1
MPTVDDILEQVGESGWFQKQAFLILCLLSAAFAPICVGIVFLGFTPDHHCQSPGVAELSQ
RCGWSPAEELNYTVPGLGPAGEAFLGQCRRYEVDWNQSALSCVDPLASLATNRSHLPLGP
CQDGWVYDTPGSSIVTEFNLVCADSWKLDLFQSCLNAGFLFGSLGVGYFADRFGRKLCLL
GTVLVNAVSGVLMAFSPNYMSMLLFRLLQGLVSKGNWMAGYTLITEFVGSGSRRTVAIMY
QMAFTVGLVALTGLAYALPHWRWLQLAVSLPTFLFLLYYWCVPESPRWLLSQKRNTEAIK
IMDHIAQKNGKLPPADLKMLSLEEDVTEKLSPSFADLFRTPRLRKRTFILMYLWFTDSVL
YQGLILHMGATSGNLYLDFLYSALVEIPGAFIALITIDRVGRIYPMAMSNLLAGAACLVM
IFISPDLHWLNIIIMCVGRMGITIAIQMICLVNAELYPTFVRNLGVMVCSSLCDIGGIIT
PFIVFRLREVWQALPLILFAVLGLLAAGVTLLLPETKGVALPETMKDAENLGRKAKPKEN
TIYLKVQTSEPSGT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017170|Solute carrier family 22 member 1 (SLC22A1)
ATGCCCACCGTGGATGACATTCTGGAGCAGGTTGGGGAGTCTGGCTGGTTCCAGAAGCAA
GCCTTCCTCATCTTATGCCTGCTGTCGGCTGCCTTTGCGCCCATCTGTGTGGGCATCGTC
TTCCTGGGTTTCACACCTGACCACCACTGCCAGAGTCCTGGGGTGGCTGAGCTGAGCCAG
CGCTGTGGCTGGAGCCCTGCGGAGGAGCTGAACTATACAGTGCCAGGCCTGGGGCCCGCG
GGCGAGGCCTTCCTTGGCCAGTGCAGGCGCTATGAAGTGGACTGGAACCAGAGCGCCCTC
AGCTGTGTAGACCCCCTGGCTAGCCTGGCCACCAACAGGAGCCACCTGCCGCTGGGTCCC
TGCCAGGATGGCTGGGTGTATGACACGCCCGGCTCTTCCATCGTCACTGAGTTCAACCTG
GTGTGTGCTGACTCCTGGAAGCTGGACCTCTTTCAGTCCTGTTTGAATGCGGGCTTCTTG
TTTGGCTCTCTCGGTGTTGGCTACTTTGCAGACAGGTTTGGCCGTAAGCTGTGTCTCCTG
GGAACTGTGCTGGTCAACGCGGTGTCGGGCGTGCTCATGGCCTTCTCGCCCAACTACATG
TCCATGCTGCTCTTCCGCCTGCTGCAGGGCCTGGTCAGCAAGGGCAACTGGATGGCTGGC
TACACCCTAATCACAGAATTTGTTGGCTCGGGCTCCAGAAGAACGGTGGCGATCATGTAC
CAGATGGCCTTCACGGTGGGGCTGGTGGCGCTTACCGGGCTGGCCTACGCCCTGCCTCAC
TGGCGCTGGCTGCAGCTGGCAGTCTCCCTGCCCACCTTCCTCTTCCTGCTCTACTACTGG
TGTGTGCCGGAGTCCCCTCGGTGGCTGTTATCACAAAAAAGAAACACTGAAGCAATAAAG
ATAATGGACCACATCGCTCAAAAGAATGGGAAGTTGCCTCCTGCTGATTTAAAGATGCTT
TCCCTCGAAGAGGATGTCACCGAAAAGCTGAGCCCTTCATTTGCAGACCTGTTCCGCACG
CCGCGCCTGAGGAAGCGCACCTTCATCCTGATGTACCTGTGGTTCACGGACTCTGTGCTC
TATCAGGGGCTCATCCTGCACATGGGCGCCACCAGCGGGAACCTCTACCTGGATTTCCTT
TACTCCGCTCTGGTCGAAATCCCGGGGGCCTTCATAGCCCTCATCACCATTGACCGCGTG
GGCCGCATCTACCCCATGGCCATGTCAAATTTGTTGGCGGGGGCAGCCTGCCTCGTCATG
ATTTTTATCTCACCTGACCTGCACTGGTTAAACATCATAATCATGTGTGTTGGCCGAATG
GGAATCACCATTGCAATACAAATGATCTGCCTGGTGAATGCTGAGCTGTACCCCACATTC
GTCAGGAACCTCGGAGTGATGGTGTGTTCCTCCCTGTGTGACATAGGTGGGATAATCACC
CCCTTCATAGTCTTCAGGCTGAGGGAGGTCTGGCAAGCCTTGCCCCTCATTTTGTTTGCG
GTGTTGGGCCTGCTTGCCGCGGGAGTGACGCTACTTCTTCCAGAGACCAAGGGGGTCGCT
TTGCCAGAGACCATGAAGGACGCCGAGAACCTTGGGAGAAAAGCAAAGCCCAAAGAAAAC
ACGATTTACCTTAAGGTCCAAACCTCAGAACCCTCGGGCACCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic cation transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quaternary ammonium group transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>secondary active organic cation transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ammonium transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epinephrine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>establishment or maintenance of transmembrane electrochemical gradient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quaternary ammonium group transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="8">
      <id>BE0003650</id>
      <name>Solute carrier family 22 member 3</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A39849</ref-id>
            <pubmed-id>20496886</pubmed-id>
            <citation>Diao L, Shu Y, Polli JE: Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7. doi: 10.1021/mp100036b.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O75751" source="Swiss-Prot">
        <name>Solute carrier family 22 member 3</name>
        <general-function>Toxin transporter activity</general-function>
        <specific-function>Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.</specific-function>
        <gene-name>SLC22A3</gene-name>
        <locus>6q26-q27</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>21-41
182-202
241-261
269-289
381-401
468-488
498-518</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.64</theoretical-pi>
        <molecular-weight>61279.485</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10967</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ001417</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3581982</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1021</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O75751</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>EMT</synonym>
          <synonym>EMTH</synonym>
          <synonym>Extraneuronal monoamine transporter</synonym>
          <synonym>OCT3</synonym>
          <synonym>Organic cation transporter 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012537|Solute carrier family 22 member 3
MPSFDEALQRVGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGTQPDHYWCRGPSAAALA
ERCGWSPEEEWNRTAPASRGPEPPERRGRCQRYLLEAANDSASATSALSCADPLAAFPNR
SAPLVPCRGGWRYAQAHSTIVSEFDLVCVNAWMLDLTQAILNLGFLTGAFTLGYAADRYG
RIVIYLLSCLGVGVTGVVVAFAPNFPVFVIFRFLQGVFGKGTWMTCYVIVTEIVGSKQRR
IVGIVIQMFFTLGIIILPGIAYFIPNWQGIQLAITLPSFLFLLYYWVVPESPRWLITRKK
GDKALQILRRIAKCNGKYLSSNYSEITVTDEEVSNPSFLDLVRTPQMRKCTLILMFAWFT
SAVVYQGLVMRLGIIGGNLYIDFFISGVVELPGALLILLTIERLGRRLPFAASNIVAGVA
CLVTAFLPEGIAWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFG
GIIAPFLLFRLAAVWLELPLIIFGILASICGGLVMLLPETKGIALPETVDDVEKLGSPHS
CKCGRNKKTPVSRSHL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012538|Solute carrier family 22 member 3 (SLC22A3)
ATGCCCTCCTTCGACGAGGCGCTGCAGCGGGTGGGCGAGTTCGGGCGCTTCCAGAGGCGC
GTGTTTTTGCTGCTGTGCCTGACGGGCGTCACCTTCGCCTTCCTCTTCGTCGGCGTGGTC
TTCCTGGGCACGCAGCCCGACCACTACTGGTGCCGCGGGCCAAGTGCCGCGGCGCTGGCC
GAGCGCTGCGGCTGGAGCCCGGAGGAGGAGTGGAACCGCACGGCGCCCGCCTCCCGCGGC
CCAGAGCCCCCCGAGCGCCGCGGCCGCTGCCAGCGCTACCTCCTGGAGGCGGCCAACGAC
AGCGCCTCCGCCACTAGCGCTCTCAGCTGCGCGGACCCACTCGCCGCCTTCCCCAACCGC
TCGGCTCCCCTTGTGCCGTGCCGCGGCGGCTGGCGCTACGCCCAGGCCCACTCCACCATC
GTCAGCGAGTTTGACCTTGTCTGTGTCAATGCGTGGATGCTGGACCTCACCCAAGCCATC
CTGAACCTCGGCTTCCTGACTGGAGCATTCACCTTAGGCTATGCAGCAGACAGGTATGGC
AGGATCGTCATTTACTTGCTATCCTGCCTTGGTGTTGGCGTCACTGGGGTTGTGGTGGCC
TTTGCACCAAACTTCCCTGTGTTTGTGATCTTCCGCTTCCTGCAAGGTGTATTTGGAAAG
GGGACGTGGATGACTTGCTACGTGATTGTGACAGAAATAGTAGGTTCGAAACAAAGGAGG
ATTGTGGGAATCGTGATTCAAATGTTCTTTACCCTTGGAATCATAATTCTCCCTGGAATT
GCCTACTTCATCCCCAACTGGCAAGGAATCCAGTTAGCCATCACGCTGCCCAGCTTTCTC
TTCCTCCTTTATTACTGGGTGGTCCCTGAGTCTCCCCGTTGGCTGATTACTCGGAAGAAA
GGAGATAAAGCATTACAGATCCTGAGACGCATTGCTAAGTGCAATGGGAAATACCTCTCA
TCAAATTACTCAGAGATCACTGTTACAGATGAGGAAGTTAGTAATCCATCCTTTTTAGAT
CTGGTGAGAACTCCCCAAATGAGGAAATGCACACTTATTCTTATGTTTGCTTGGTTCACA
AGCGCAGTGGTGTATCAAGGACTTGTCATGCGCCTGGGAATTATAGGGGGCAACCTCTAT
ATAGACTTTTTCATCTCGGGCGTGGTGGAACTGCCAGGAGCTCTCTTGATCTTACTAACC
ATTGAGCGCCTTGGACGACGCCTCCCCTTTGCGGCAAGCAATATAGTGGCAGGGGTGGCA
TGCCTTGTCACTGCGTTCTTACCAGAAGGAATAGCATGGTTGAGGACCACAGTGGCTACA
TTGGGAAGACTAGGGATAACCATGGCCTTTGAAATTGTTTATTTGGTAAATTCAGAATTG
TACCCAACAACATTACGAAATTTCGGAGTTTCGCTCTGTTCAGGTCTGTGTGATTTTGGG
GGAATCATAGCCCCATTTCTGCTCTTTCGGCTAGCAGCCGTGTGGCTAGAACTACCTCTG
ATCATCTTTGGTATCCTGGCATCCATCTGTGGTGGCCTTGTGATGCTTTTGCCTGAAACC
AAGGGTATTGCCTTGCCAGAGACAGTGGATGATGTAGAAAAACTTGGCAGTCCACATTCC
TGTAAATGTGGCAGGAATAAGAAAACCCCAGTTTCCCGCTCTCACCTTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07690</identifier>
            <name>MFS_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic cation transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quaternary ammonium group transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxin transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ammonium transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>histamine uptake</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quaternary ammonium group transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of appetite</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>